

## FULL PRESCRIBING INFORMATION

### 1. NAME OF THE MEDICINAL PRODUCT

Bortezomib Taro 3.5 mg

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 3.5 mg bortezomib (as a mannitol boronic ester).

After reconstitution, each 1 mL of solution for subcutaneous injection contains 2.5 mg bortezomib.

After reconstitution, each 1 mL of solution for intravenous injection contains 1 mg bortezomib.

For the full list of excipients, see section 12.

### Pharmaceutical Form

Powder for Solution for Injection

### 3. THERAPEUTIC INDICATIONS

#### 3.2 Multiple Myeloma

Bortezomib Taro 3.5 mg is indicated for the treatment of patients with multiple myeloma.

#### 3.3 Mantle Cell Lymphoma

Bortezomib Taro 3.5 mg is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

Bortezomib Taro 3.5 mg in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

### 4. DOSAGE AND ADMINISTRATION

#### General Dosing Guidelines

**BORTEZOMIB TARO 3.5 MG IS FOR INTRAVENOUS OR SUBCUTANEOUS USE ONLY.** Bortezomib Taro 3.5 mg must not be administered by any other route. Intrathecal administration has resulted in death.

**Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered.**

The recommended starting dose of Bortezomib Taro 3.5 mg is 1.3 mg/m<sup>2</sup>. Bortezomib Taro 3.5 mg may be administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL (*see reconstitution/preparation for intravenous and subcutaneous administration (section 4.8)*). When administered intravenously, Bortezomib Taro 3.5 mg is administered as a 3 to 5 second bolus intravenous injection.

#### 4.1 Dosage in Previously Untreated Multiple Myeloma

Bortezomib Taro is administered in combination with oral melphalan and oral prednisone for 9 six-week treatment cycles as shown in Table 1. In Cycles 1 to 4, Bortezomib Taro is administered twice weekly (Days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5 to 9, Bortezomib Taro is administered once weekly (Days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of Bortezomib Taro.

**TABLE 1 - Dosage Regimen for Patients with Previously Untreated Multiple Myeloma**

Twice Weekly Bortezomib Taro (Cycles 1 to 4)												
Week	1				2		3	4		5		6
Bortezomib Taro (1.3 mg/m <sup>2</sup> )	Day 1			Day 4	Day 8	Day 11	rest period	Day 22	Day 25	Day 29	Day 32	rest period
Melphalan (9 mg/m <sup>2</sup> ) Prednisone (60 mg/m <sup>2</sup> )	Day 1	Day 2	Day 3	Day 4			rest period					rest period

**Once Weekly Bortezomib Taro (Cycles 5 to 9 when used in combination with Melphalan and Prednisone)**

Week	1				2		3	4		5		6
Bortezomib Taro (1.3 mg/m <sup>2</sup> )	Day 1				Day 8		rest period	Day 22		Day 29		rest period
Melphalan (9 mg/m <sup>2</sup> ) Prednisone (60 mg/m <sup>2</sup> )	Day 1	Day 2	Day 3	Day 4			rest period					rest period

#### 4.2 Dose Modification Guidelines for Combination Therapy with Bortezomib Taro, Melphalan and Prednisone

Prior to initiating any cycle of therapy with Bortezomib Taro in combination with melphalan and prednisone:

- Platelet count should be  $\geq 70 \times 10^9/L$  and the absolute neutrophil count (ANC) should be  $\geq 1.0 \times 10^9/L$ .
- Non-hematological toxicities should have resolved to Grade 1 or baseline.

**TABLE 2 – Dose Modifications During Cycles of Combination Bortezomib Taro, Melphalan and Prednisone Therapy**

Toxicity	Dose Modification or Delay
Hematological toxicity during a cycle: If prolonged grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle	Consider reduction of the melphalan dose by 25% in the next cycle
If platelet count is not above $30 \times 10^9/L$ or ANC is not above $0.75 \times 10^9/L$ on a Bortezomib dosing day (other than day 1)	Withhold Bortezomib Taro dose
If several Bortezomib Taro doses in consecutive cycles are withheld due to toxicity	Reduce Bortezomib Taro dose by one dose level (from 1.3 mg/m <sup>2</sup> to 1 mg/m <sup>2</sup> , or from 1 mg/m <sup>2</sup> to 0.7 mg/m <sup>2</sup> )
Grade 3 or higher non-hematological toxicities	Withhold Bortezomib Taro therapy until symptoms of toxicity have resolved to Grade 1 or baseline. Then, Bortezomib

**TABLE 2 – Dose Modifications During Cycles of Combination Bortezomib Taro, Melphalan and Prednisone Therapy**

Toxicity	Dose Modification or Delay
	Taro may be reinitiated with one dose level reduction (from 1.3 mg/m <sup>2</sup> to 1 mg/m <sup>2</sup> , or from 1 mg/m <sup>2</sup> to 0.7 mg/m <sup>2</sup> ). For Bortezomib Taro-related neuropathic pain and/or peripheral neuropathy, hold or modify Bortezomib Taro as outlined in Table 4.

For information concerning melphalan and prednisone, see manufacturer’s prescribing information.

Dose modifications guidelines for peripheral neuropathy are provided [*See Dosage and Administration (4.6)*].

### 4.3 Posology for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

*Combination therapy with rituximab, cyclophosphamide, doxorubicin and prednisone (VcR-CAP)*

Bortezomib Taro 3.5 mg powder for solution for injection is administered via intravenous injection at the recommended dose of 1.3 mg/m<sup>2</sup> body surface area twice weekly for two weeks on days 1, 4, 8, and 11 followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. Six Bortezomib Taro cycles are recommended, although for patients with a response first documented at cycle 6, two additional Bortezomib Taro cycles may be given. At least 72 hours should elapse between consecutive doses of Bortezomib Taro.

The following medicinal products are administered on day 1 of each Bortezomib Taro 3-week treatment cycle as intravenous infusions: rituximab at 375 mg/m<sup>2</sup>, cyclophosphamide at 750 mg/m<sup>2</sup> and doxorubicin at 50 mg/m<sup>2</sup>. Prednisone is administered orally at 100 mg/m<sup>2</sup> on days 1, 2, 3, 4 and 5 of each Bortezomib Taro treatment cycle.

*Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma*

Prior to initiating a new cycle of therapy:

- Platelet counts should be  $\geq 100,000$  cells/ $\mu$ L and the absolute neutrophils count (ANC) should be  $\geq 1,500$  cells/ $\mu$ L
- Platelet counts should be  $\geq 75,000$  cells/ $\mu$ L in patients with bone marrow infiltration or splenic sequestration
- Haemoglobin  $\geq 8$  g/dL
- Non-haematological toxicities should have resolved to Grade 1 or baseline.

Bortezomib Taro treatment must be withheld at the onset of any  $\geq$  Grade 3 Bortezomib Taro-related non-haematological toxicities (excluding neuropathy) or  $\geq$  Grade 3 haematological toxicities. For dose adjustments, see Table 3 below.

Granulocyte colony stimulating factors may be administered for haematologic toxicity according to local standard practice. Prophylactic use of granulocyte colony stimulating factors should be considered in case of repeated delays in cycle administration. Platelet transfusion for the treatment of thrombocytopenia should be considered when clinically appropriate.

**TABLE 3 - Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma**

<b>Toxicity</b>	<b>Dose modification or delay</b>
<i>Haematological toxicity</i>	
≥ Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, a platelet count < 10,000 cells/μL	Bortezomib therapy should be withheld for up to 2 weeks until the patient has an ANC ≥ 750 cells/μL and a platelet count ≥ 25,000 cells/μL. <ul style="list-style-type: none"> <li>•If, after Bortezomib Taro has been held, the toxicity does not resolve, as defined above, then Bortezomib Taro must be discontinued.</li> <li>•If toxicity resolves i.e., patient has an ANC ≥ 750 cells/μL and a platelet count ≥ 25,000 cells/μL, Bortezomib Taro may be reinitiated at a dose reduced by one dose level (from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup>, or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>).</li> </ul>
If platelet count < 25,000 cells/μL or ANC < 750 cells/μL on a Bortezomib Taro dosing day (other than Day 1 of each cycle)	Bortezomib Taro therapy should be withheld.
If several Bortezomib Taro doses in consecutive cycles are withheld due to toxicity	Reduce Bortezomib Taro dose by one dose level (from 1.3 mg/m <sup>2</sup> to 1 mg/m <sup>2</sup> , or from 1 mg/m <sup>2</sup> to 0.7 mg/m <sup>2</sup> )
Grade ≥ 3 non-hematological toxicities considered to be related to Bortezomib Taro	Bortezomib Taro therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better. Then, Bortezomib Taro may be reinitiated at a dose reduced by one dose level (from 1.3 mg/m <sup>2</sup> to 1 mg/m <sup>2</sup> , or from 1 mg/m <sup>2</sup> to 0.7 mg/m <sup>2</sup> ). For Bortezomib Taro-related neuropathic pain and/or peripheral neuropathy, hold and/or modify Bortezomib Taro as outlined in Table 1.

In addition, when Bortezomib Taro is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these medicinal products should be considered in the event of toxicities, according to the recommendations in the respective Summary of Product Characteristics.

#### **4.4 Dosage in Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma**

Bortezomib Taro (1.3 mg/m<sup>2</sup>/dose) is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a ten-day rest period (Days 12 to 21). For extended therapy of more than eight cycles, Bortezomib Taro may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for four weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35) [see *Clinical Studies section (15) for a description of dose administration during the trials*]. At least 72 hours should elapse between consecutive doses of Bortezomib Taro.

#### **4.5 Dose Modification Guidelines for Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma**

Bortezomib Taro therapy should be withheld at the onset of any Grade 3 non-hematological or Grade 4 hematological toxicities excluding neuropathy as discussed below [see *Warnings and Precautions (5)*]. Once the symptoms of the toxicity have resolved, Bortezomib Taro therapy may be reinitiated at a 25% reduced dose (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).

For dose modifications guidelines for peripheral neuropathy, see Management of Peripheral Neuropathy section (4.6).

#### 4.6 Dose Modifications of Peripheral Neuropathy

Starting Bortezomib Taro subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy. Patients with pre-existing severe neuropathy should be treated with Bortezomib Taro only after careful risk-benefit assessment.

Patients experiencing new or worsening peripheral neuropathy during Bortezomib Taro therapy may require a decrease in the dose and/or a less dose-intensive schedule.

For dose or schedule modification guidelines for patients who experience Bortezomib Taro-related neuropathic pain and/or peripheral neuropathy, see Table 4.

**TABLE 4 – Recommended Dose Modification for Bortezomib Taro-Related Neuropathic Pain and/or Peripheral Sensory or Motor Neuropathy**

Severity of Peripheral Neuropathy Signs and Symptoms*	Modification of Dose and Regimen
Grade 1 (asymptomatic; loss of deep tendon reflexes or paresthesia) without pain or loss of function	No action
Grade 1 with pain or Grade 2 (moderate symptoms; limiting Instrumental Activities of Daily Living (ADL))**	Reduce Bortezomib Taro to 1 mg/m <sup>2</sup> OR Change Bortezomib Taro treatment schedule to 1.3 mg/m <sup>2</sup> once per week
Grade 2 with pain or Grade 3 (severe symptoms; limiting Self-care (ADL))***	Withhold Bortezomib Taro therapy until toxicity resolves. When toxicity resolves reinstate with a reduced dose of Bortezomib Taro at 0.7 mg/m <sup>2</sup> once per week.
Grade 4 (life-threatening consequences; urgent intervention indicated)	Discontinue Bortezomib Taro

\* Grading based on NCI Common Toxicity Criteria CTCAE v 4.0

\*\* Instrumental ADL: refers to preparing meals, shopping for groceries or clothes, using telephone, managing money etc.

\*\*\* Self-care ADL: refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden

#### 4.7 Dosage in Patients with Hepatic Impairment

Patients with mild hepatic impairment do not require a dose adjustment and should be treated per the recommended Bortezomib Taro dose. Patients with moderate or severe hepatic impairment should be started on Bortezomib Taro at a reduced dose of 0.7 mg/m<sup>2</sup> per injection during the first cycle, and a subsequent dose escalation to 1.0 mg/m<sup>2</sup> or further dose reduction to 0.5 mg/m<sup>2</sup> may be considered based on patient tolerance (see Table 5) [see *Warnings and Precautions (7.8), Use in Specific Populations (10.7) and Clinical Pharmacology (13.3)*].

**TABLE 5 - Recommended Starting Dose Modification for Bortezomib Taro in Patients with Hepatic Impairment**

Grade of hepatic impairment*	Bilirubin Level	SGOT (AST) Levels	Modification of Starting Dose
Mild	Less than or equal to 1.0 x ULN	> ULN	None

Grade of hepatic impairment*	Bilirubin Level	SGOT (AST) Levels	Modification of Starting Dose
	More than 1.0 x to 1.5 x ULN	Any	None
Moderate	More than 1.5 x to 3 x ULN	Any	Reduce Bortezomib Taro to 0.7 mg/m <sup>2</sup> in the first treatment cycle. Consider dose escalation to 1 mg/m <sup>2</sup> or further dose reduction to 0.5 mg/m <sup>2</sup> in subsequent cycles based on patient tolerability.
Severe	More than 3 x ULN	Any	

Abbreviations: SGOT = serum glutamic oxaloacetic transaminase;

AST = aspartate aminotransferase; ULN = upper limit of the normal range

\*Based on NCI Organ Dysfunction Working Group classification for categorising hepatic impairment (mild, moderate, severe).

#### 4.8 Administration Precautions

The drug quantity contained in one vial (3.5 mg) may exceed the usual dose required. Caution should be used in calculating the dose to prevent overdose (*see Reconstitution/Preparation for Intravenous and Subcutaneous Administration (section 4.9)*).

Bortezomib Taro 3.5 mg is authorized for intravenous or subcutaneous use only. Intrathecal administration has resulted in death.

When administered subcutaneously, sites for each injection (thigh or abdomen) should be rotated. New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, erythematous, or indurated.

If local injection site reactions occur following bortezomib administration subcutaneously, a less concentrated bortezomib solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously [*see Reconstitution/Preparation for Intravenous and Subcutaneous Administration (section 4.9)*] and follow reconstitution instructions for 1 mg/mL].

Alternatively, the intravenous route of administration should be considered [*see Reconstitution/Preparation for Intravenous and Subcutaneous Administration (section 4.9)*].

Bortezomib Taro 3.5 mg is a cytotoxic drug. Follow applicable special handling and disposal procedures [*See How Supplied/Storage and Handling (16)*].

#### 4.9 Reconstitution/Preparation for Intravenous and Subcutaneous Administration

Use proper aseptic technique. Reconstitute **only with 0.9% sodium chloride**. The reconstituted product should be a clear and colorless solution.

Different volumes of 0.9% sodium chloride are used to reconstitute the product for the different routes of administration. The reconstituted concentration of bortezomib for subcutaneous administration (2.5 mg/mL) is greater than the reconstituted concentration of bortezomib for intravenous administration (1 mg/mL).

**Because each route of administration has a different reconstituted concentration, use caution when calculating the volume to be administered** (*see Administration Precautions section 4.8*).

For each 3.5 mg single-dose vial of bortezomib, reconstitute with the following volume of 0.9% sodium chloride based on route of administration (Table 6):

**TABLE 6 - Reconstitution Volumes and Final Concentration for Intravenous and Subcutaneous Administration**

<b>Route of Administration</b>	<b>Bortezomib Taro (mg/vial)</b>	<b>Diluent (0.9% Sodium Chloride)</b>	<b>Final Bortezomib Taro concentration (mg/mL)</b>
Intravenous	3.5 mg	3.5 mL	1 mg/mL
Subcutaneous	3.5 mg	1.4 mL	2.5 mg/mL

Dose must be individualized to prevent overdosage. After determining patient body surface area (BSA) in square meters, use the following equations to calculate the total volume (mL) of reconstituted Bortezomib Taro 3.5 mg to be administered:

**•Intravenous Administration [1 mg/mL concentration]**

$$\frac{\text{Bortezomib dose (mg/m}^2\text{)} \times \text{patient BSA (m}^2\text{)}}{1 \text{ mg/mL}} = \text{Total Bortezomib volume (mL) to be administered}$$

**•Subcutaneous Administration [2.5 mg/mL concentration]**

$$\frac{\text{Bortezomib dose (mg/m}^2\text{)} \times \text{patient BSA (m}^2\text{)}}{2.5 \text{ mg/mL}} = \text{Total Bortezomib volume (mL) to be administered}$$

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If any discoloration or particulate matter is observed, the reconstituted product should not be used.

***Stability***

Unopened vials of Bortezomib Taro 3.5 mg are stable until the date indicated on the package when stored in the original package protected from light.

Do not store above 25°C.

**Bortezomib Taro 3.5 mg contains no antimicrobial preservative.**

From a microbiological point of view, the reconstituted solution should be used immediately after preparation. If the reconstituted solution is not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. However, the chemical and physical in-use stability of the reconstituted solution has been demonstrated for 8 hours at 25°C stored in the original vial and/or a syringe prior to administration.

The total storage time for the reconstituted medicinal product should not exceed 8 hours prior to administration.

**5. DOSAGE FORMS AND STRENGTHS**

Each single dose vial of Bortezomib Taro 3.5 mg contains 3.5 mg of bortezomib as a sterile lyophilized white to off-white powder or cake for reconstitution and withdrawal of the appropriate individual patient dose [see Dosage and Administration (section 4)].

**6. CONTRAINDICATIONS**

Bortezomib Taro is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [see Adverse Reactions (8.1)].

Bortezomib Taro is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of Bortezomib Taro.

## **7. WARNINGS AND PRECAUTIONS**

### **7.1 Peripheral Neuropathy**

Bortezomib Taro treatment causes a peripheral neuropathy that is predominantly sensory. However, cases of severe sensory and motor peripheral neuropathy have been reported. Patients with pre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy (including  $\geq$  Grade 3) during treatment with Bortezomib Taro. Patients should be monitored for symptoms of neuropathy, such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness. In the Phase 3 relapsed multiple myeloma trial comparing Bortezomib Taro subcutaneous vs intravenous, the incidence of Grade  $\geq 2$  peripheral neuropathy was 24% for subcutaneous and 39% for intravenous.

Grade  $\geq 3$  peripheral neuropathy occurred in 6% of patients in the subcutaneous treatment group, compared with 15% in the intravenous treatment group [*See Adverse Reactions (8.1)*]. Starting Bortezomib Taro subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy.

Patients experiencing new or worsening peripheral neuropathy during Bortezomib Taro therapy may require a decrease in the dose and/or a less dose-intense schedule [*see Dosage and Administration (4)*].

In the Bortezomib Taro vs dexamethasone Phase 3 relapsed multiple myeloma study, improvement in or resolution of peripheral neuropathy was reported in 48% of patients with  $\geq$  Grade 2 peripheral neuropathy following dose adjustment or interruption. Improvement in or resolution of peripheral neuropathy was reported in 73% of patients who discontinued due to Grade 2 neuropathy or who had  $\geq$  Grade 3 peripheral neuropathy in the Phase 2 multiple myeloma studies. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma.

### **7.2 Hypotension**

The incidence of hypotension (postural, orthostatic, and hypotension NOS) was 8% [*see Adverse Reactions (8.1)*]. These events are observed throughout therapy. Patients with a history of syncope, patients receiving medications known to be associated with hypotension, and patients who are dehydrated may be at increased risk of hypotension. Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics.

### **7.3 Cardiac Toxicity**

Acute development or exacerbation of congestive heart failure and new onset of decreased left ventricular ejection fraction have occurred during Bortezomib Taro therapy, including reports in patients with no risk factors for decreased left ventricular ejection fraction [*see Adverse Reactions (8.1)*]. Patients with risk factors for, or existing heart disease should be closely monitored. In the relapsed multiple myeloma study of Bortezomib Taro vs dexamethasone, the incidence of any treatment-related cardiac disorder was 8% and 5% in the Bortezomib Taro and dexamethasone groups, respectively. The incidence of adverse reactions suggestive of heart failure (acute pulmonary edema, cardiac failure, congestive cardiac failure, cardiogenic shock, pulmonary edema) was  $\leq 1\%$  for each individual reaction in the



Bortezomib Taro group. In the dexamethasone group the incidence was  $\leq 1\%$  for cardiac failure and congestive cardiac failure; there were no reported reactions of acute pulmonary edema, pulmonary edema, or cardiogenic shock.

There have been isolated cases of QT-interval prolongation in clinical studies; causality has not been established.

#### **7.4 Pulmonary Toxicity**

Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration have occurred in patients receiving Bortezomib Taro. Some of these events have been fatal.

In a clinical trial, the first two patients given high-dose cytarabine (2 g/m<sup>2</sup> per day) by continuous infusion with daunorubicin and Bortezomib Taro for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy.

There have been reports of pulmonary hypertension associated with Bortezomib Taro administration in the absence of left heart failure or significant pulmonary disease.

In the event of new or worsening cardiopulmonary symptoms, consider interrupting Bortezomib Taro until a prompt and comprehensive diagnostic evaluation is conducted.

#### **7.5 Posterior Reversible Encephalopathy Syndrome (PRES)**

Posterior Reversible Encephalopathy Syndrome (PRES; formerly termed Reversible Posterior Leukoencephalopathy Syndrome (RPLS)) has occurred in patients receiving Bortezomib Taro. PRES is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. Brain imaging, preferably MRI (Magnetic Resonance Imaging), is used to confirm the diagnosis. In patients developing PRES, discontinue Bortezomib Taro. The safety of reinitiating Bortezomib Taro therapy in patients previously experiencing PRES is not known.

#### **7.6 Gastrointestinal Toxicity**

Bortezomib treatment can cause nausea, diarrhea, constipation, and vomiting [*see Adverse Reactions (8.1)*] sometimes requiring use of antiemetic and antidiarrheal medications. Ileus can occur. Fluid and electrolyte replacement should be administered to prevent dehydration. Interrupt Bortezomib Taro for severe symptoms.

#### **7.7 Thrombocytopenia/Neutropenia**

Bortezomib Taro is associated with thrombocytopenia and neutropenia that follow a cyclical pattern with nadirs occurring following the last dose of each cycle and typically recovering prior to initiation of the subsequent cycle. The cyclical pattern of platelet and neutrophil decreases and recovery remain consistent in the studies of multiple myeloma and mantle cell lymphoma, with no evidence of cumulative thrombocytopenia or neutropenia in the treatment regimens studied.

Monitor complete blood counts (CBC) frequently during treatment with Bortezomib Taro. Measure platelet counts prior to each dose of Bortezomib Taro. Adjust dose/schedule for thrombocytopenia [*see Tables 6 and 7, Dosage and Administration (4)*]. Gastrointestinal and intracerebral hemorrhage has occurred during thrombocytopenia in association with

Bortezomib Taro. Support with transfusions and supportive care, according to published guidelines.

In the single-agent, relapsed multiple myeloma study of Bortezomib Taro vs dexamethasone, the mean platelet count nadir measured was approximately 40% of baseline. The severity of thrombocytopenia related to pretreatment platelet count is shown in Table 7. The incidence of bleeding ( $\geq$  Grade 3) was 2% on the Bortezomib Taro arm and was  $<$  1% in the dexamethasone arm.

**TABLE 7 - Severity of Thrombocytopenia Related to Pretreatment Platelet Count in the Relapsed Multiple Myeloma Study of Bortezomib Taro vs Dexamethasone**

<b>Pretreatment Platelet Count*</b>	<b>Number of Patients (n=331)**</b>	<b>Number (%) of Patients with Platelet Count <math>&lt;</math> 10,000/<math>\mu</math>L</b>	<b>Number (%) of Patients with Platelet Count 10,000-25,000/<math>\mu</math>L</b>
$\geq$ 75,000/ $\mu$ L	309	8 (3%)	36 (12%)
$\geq$ 50,000/ $\mu$ L to $<$ 75,000/ $\mu$ L	14	2 (14%)	11 (79%)
$\geq$ 10,000/ $\mu$ L to $<$ 50,000/ $\mu$ L	7	1 (14%)	5 (71%)

\*A baseline platelet count of 50,000/ $\mu$ L was required for study eligibility.

\*\*Data were missing at baseline for one patient.

In the combination study of Bortezomib Taro with rituximab, cyclophosphamide, doxorubicin and prednisone (VcR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia ( $\geq$  Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12. The incidence of bleeding events ( $\geq$  Grade 3) was 1.7% in the VcR-CAP arm (four patients) and was 1.2% in the R-CHOP arm (three patients).

Platelet transfusions were given to 23% of the patients in the VcR-CAP arm and 3% of the patients in the R-CHOP arm.

The incidence of neutropenia ( $\geq$  Grade 4) was 70% in the VcR-CAP arm and was 52% in the R-CHOP arm. The incidence of febrile neutropenia ( $\geq$  Grade 4) was 5% in the VcR-CAP arm and was 6% in the R-CHOP arm. Myeloid growth factor support was provided at a rate of 78% in the VcR-CAP arm and 61% in the R-CHOP arm.

## 7.8 Hepatic Impairment

Bortezomib is metabolised by liver enzymes. Bortezomib exposure is increased in patients with moderate or severe hepatic impairment; these patients should be treated with Bortezomib Taro at reduced doses and closely monitored for toxicities (*see sections 4.7 and 13.3*).

## 7.9 Tumor Lysis Syndrome

Tumor lysis syndrome has been reported with Bortezomib Taro therapy. Patients at risk of tumor lysis syndrome are those with high tumor burden prior to treatment. Monitor patients closely and take appropriate precautions.

## 7.10 Hepatic Toxicity

Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Other reported hepatic reactions include hepatitis, increases in liver enzymes, and hyperbilirubinemia. Interrupt Bortezomib Taro therapy to assess reversibility. There is limited re-challenge information in these patients.

## 7.11 Thrombotic Microangiopathy

Cases, sometimes fatal, of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), have been reported in the postmarketing setting in patients who received Bortezomib Taro. Monitor for signs and symptoms of TTP/HUS. If the diagnosis is suspected, stop Bortezomib Taro and evaluate. If the diagnosis of TTP/HUS is excluded, consider restarting Bortezomib Taro. The safety of reinitiating Bortezomib Taro therapy in patients previously experiencing TTP/HUS is not known.

## 7.12 Embryo-Fetal Toxicity

Based on the mechanism of action and findings in animals, Bortezomib Taro can cause fetal harm when administered to a pregnant woman. Bortezomib administered to rabbits during organogenesis at a dose approximately 0.5 times the clinical dose of 1.3 mg/m<sup>2</sup> based on body surface area caused post-implantation loss and a decreased number of live fetuses [*see Use in Specific Populations (10.1)*].

Advise females of reproductive potential to use effective contraception during treatment with Bortezomib Taro and for seven months following treatment. Advise males with female partners of reproductive potential to use effective contraception during treatment with Bortezomib Taro and for four months following treatment. If Bortezomib Taro is used during pregnancy or if the patient becomes pregnant during Bortezomib Taro treatment, the patient should be apprised of the potential risk to the fetus only present in copy [*see Use in Specific Populations (10.1, 10.3), Nonclinical Toxicology (14.1)*].

## 7.13 Herpes Zoster Virus Reactivation

Antiviral prophylaxis is recommended in patients being treated with Bortezomib.

In patients with MCL (study LYM-3002), the incidence of herpes zoster infection was 6.7% in the VcR-CAP arm and 1.2% in the R-CHOP arm.

## 7.14 Progressive Multifocal Leukoencephalopathy (PML)

Very rare cases with unknown causality of John Cunningham (JC) virus infection, resulting in PML and death, have been reported in patients treated with Bortezomib Taro. Patients diagnosed with PML had prior or concurrent immunosuppressive therapy. Most cases of PML were diagnosed within 12 months of their first dose of Bortezomib Taro. Patients should be monitored at regular intervals for any new or worsening neurological symptoms or signs that may be suggestive of PML as part of the differential diagnosis of CNS problems. If a diagnosis of PML is suspected, patients should be referred to a specialist in PML and appropriate diagnostic measures for PML should be initiated. Discontinue Bortezomib Taro if PML is diagnosed.

### **7.15 Seizures**

Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy. Special care is required when treating patients with any risk factors for seizures.

### **7.16 Renal Impairment**

Renal complications are frequent in patients with multiple myeloma. Patients with renal impairment should be monitored closely.

### **7.17 Concomitant Medicinal Products**

Patients should be closely monitored when given bortezomib in combination with potent CYP3A4-inhibitors. Caution should be exercised when bortezomib is combined with CYP3A4 or CYP2C19 substrates.

Normal liver function should be confirmed, and caution should be exercised in patients receiving oral hypoglycemics.

### **7.18 Potentially Immunocomplex-mediated Reactions**

Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly. Bortezomib should be discontinued if serious reactions occur.

### **7.19 Hepatitis B Virus (HBV) Reactivation and Infection**

When rituximab is used in combination with Bortezomib Taro, HBV screening must always be performed in patients at risk of infection with HBV before initiation of treatment. Carriers of hepatitis B and patients with a history of hepatitis B must be closely monitored for clinical and laboratory signs of active HBV infection during and following rituximab combination treatment with Bortezomib Taro.

Antiviral prophylaxis should be considered. Refer to the Summary of Product Characteristics of rituximab for more information.

### **7.20 Haematological Toxicity**

Bortezomib Taro treatment is very commonly associated with haematological toxicities (thrombocytopenia, neutropenia and anaemia). In studies in patients with relapsed multiple myeloma treated with Bortezomib Taro and in patients with previously untreated MCL treated with Bortezomib Taro in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP), one of the most common haematologic toxicity was transient thrombocytopenia. Platelets were lowest at Day 11 of each cycle of Bortezomib Taro treatment and typically recovered to baseline by the next cycle. There was no evidence of cumulative thrombocytopenia. The mean platelet count nadir measured was approximately 40% of baseline in the single-agent multiple myeloma studies and 50% in the MCL study. In patients with advanced myeloma the severity of thrombocytopenia was related to pre-treatment platelet count: for baseline platelet counts < 75,000/ $\mu$ l, 90% of 21 patients had a count  $\leq$  25,000/ $\mu$ l during the study, including 14% < 10,000/ $\mu$ l; in contrast, with a baseline platelet count > 75,000/ $\mu$ l, only 14% of 309 patients had a count  $\leq$  25,000/ $\mu$ l during the study.

In patients with MCL (study LYM-3002), there was a higher incidence (56.7% vs 5.8%) of Grade  $\geq$  3 thrombocytopenia in the Bortezomib Taro treatment group (VcR-CAP) as

compared to the non- Bortezomib Taro treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]). The two treatment groups were similar with regard to the overall incidence of all-grade bleeding events (6.3% in the VcR-CAP group and 5.0% in the R-CHOP group) as well as Grade 3 and higher bleeding events (VcR-CAP: 4 patients [1.7%]; R-CHOP: 3 patients [1.2%]). In the VcR-CAP group, 22.5% of patients received platelet transfusions compared to 2.9% of patients in the R-CHOP group.

Gastrointestinal and intracerebral haemorrhage, have been reported in association with Bortezomib Taro treatment. Therefore, platelet counts should be monitored prior to each dose of Bortezomib Taro. Bortezomib Taro therapy should be withheld when the platelet count is < 25,000/ $\mu$ l or, in the case of combination with melphalan and prednisone, when the platelet count is  $\leq$  30,000/ $\mu$ l (see section 5.3). Potential benefit of the treatment should be carefully weighed against the risks, particularly in case of moderate to severe thrombocytopenia and risk factors for bleeding.

Complete blood counts (CBC) with differential and including platelet counts should be frequently monitored throughout treatment with Bortezomib Taro. Platelet transfusion should be considered when clinically appropriate (see section 4.3).

In patients with MCL, transient neutropenia that was reversible between cycles was observed, with no evidence of cumulative neutropenia. Neutrophils were lowest at Day 11 of each cycle of Bortezomib Taro treatment and typically recovered to baseline by the next cycle. In study LYM-3002, colony stimulating factor support was given to 78% of patients in the VcR-CAP arm and 61% of patients in the R-CHOP arm. Since patients with neutropenia are at increased risk of infections, they should be monitored for signs and symptoms of infection and treated promptly. Granulocyte colony stimulating factors may be administered for haematologic toxicity according to local standard practice. Prophylactic use of granulocyte colony stimulating factors should be considered in case of repeated delays in cycle administration (see section 4.3).

### **7.21 Intrathecal Administration**

There have been fatal cases of inadvertent intrathecal administration of Bortezomib Taro. Bortezomib Taro 3.5 mg powder for solution for injection is for intravenous or subcutaneous use. Bortezomib Taro should not be administered intrathecally.

### **7.22 Electrocardiogram Investigations**

There have been isolated cases of QT-interval prolongation in clinical studies, causality has not been established.

## **8. ADVERSE REACTIONS**

The following adverse events are also discussed in other sections of the labeling:

- Peripheral Neuropathy [*see Warnings and Precautions (7.1)*]
- Hypotension [*see Warnings and Precautions (7.2)*]
- Cardiac Toxicity [*see Warnings and Precautions (7.3)*]
- Pulmonary Toxicity [*see Warnings and Precautions (7.4)*]
- Posterior Reversible Encephalopathy Syndrome (PRES) [*see Warnings and Precautions (7.5)*]
- Gastrointestinal Toxicity [*see Warnings and Precautions (7.6)*]

- Thrombocytopenia/Neutropenia [see Warnings and Precautions (7.7)]
- Tumor Lysis Syndrome [see Warnings and Precautions (7.8)]
- Hepatic Toxicity [see Warnings and Precautions (7.9)]
- Thrombotic Microangiopathy [see Warnings and Precautions (7.11)]

## 8.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

### **Summary of Clinical Trial in Patients with Previously Untreated Multiple Myeloma:**

Table 8 describes safety data from 340 patients with previously untreated multiple myeloma who received Bortezomib Taro (1.3 mg/m<sup>2</sup>) administered intravenously in combination with melphalan (9 mg/m<sup>2</sup>) and prednisone (60 mg/m<sup>2</sup>) in a prospective randomized study.

The safety profile of Bortezomib Taro in combination with melphalan/prednisone is consistent with the known safety profiles of both Bortezomib Taro and melphalan/prednisone.

**TABLE 8 - Most Commonly Reported Adverse Reactions (≥ 10% in Bortezomib Taro, Melphalan and Prednisone Arm) with Grades 3 and ≥ 4 Intensity in the Previously Untreated Multiple Myeloma Study**

Body System	Bortezomib Taro, Melphalan and Prednisone (n=340)			Melphalan and Prednisone (n=337)		
	Total n (%)	Toxicity Grade, n (%)		Total n (%)	Toxicity Grade, n (%)	
Adverse Reaction	n (%)	3	≥ 4	n (%)	3	≥ 4
<b>Blood and Lymphatic System Disorders</b>						
Thrombocytopenia	164 (48)	60 (18)	57 (17)	140 (42)	48 (14)	39 (12)
Neutropenia	160 (47)	101 (30)	33 (10)	143 (42)	77 (23)	42 (12)
Anemia	109 (32)	41 (12)	4 (1)	156 (46)	61 (18)	18 (5)
Leukopenia	108 (32)	64 (19)	8 (2)	93 (28)	53 (16)	11 (3)
Lymphopenia	78 (23)	46 (14)	17 (5)	51 (15)	26 (8)	7 (2)
<b>Gastrointestinal Disorders</b>						
Nausea	134 (39)	10 (3)	0	70 (21)	1 (< 1)	0
Diarrhea	119 (35)	19 (6)	2 (1)	20 (6)	1 (< 1)	0
Vomiting	87 (26)	13 (4)	0	41 (12)	2 (1)	0
Constipation	77 (23)	2 (1)	0	14 (4)	0	0
Abdominal pain upper	34 (10)	1 (< 1)	0	20 (6)	0	0
<b>Nervous System Disorders</b>						
Peripheral neuropathy*	156 (46)	42 (12)	2 (1)	4 (1)	0	0
Neuralgia	117 (34)	27 (8)	2 (1)	1 (< 1)	0	0
Paresthesia	42 (12)	6 (2)	0	4 (1)	0	0
<b>General Disorders and Administration Site Conditions</b>						
Fatigue	85 (25)	19 (6)	2 (1)	48 (14)	4 (1)	0
Asthenia	54 (16)	18 (5)	0	23 (7)	3 (1)	0
Pyrexia	53 (16)	4 (1)	0	19 (6)	1 (< 1)	1 (< 1)
<b>Infections and Infestations</b>						
Herpes Zoster	39 (11)	11 (3)	0	9 (3)	4 (1)	0
<b>Metabolism and Nutrition Disorders</b>						
Anorexia	64 (19)	6 (2)	0	19 (6)	0	0

	Bortezomib Taro, Melphalan and Prednisone (n=340)			Melphalan and Prednisone (n=337)		
Body System	Total	Toxicity Grade, n (%)		Total	Toxicity Grade, n (%)	
Adverse Reaction	n (%)	3	≥ 4	n (%)	3	≥ 4
<b>Skin and Subcutaneous Tissue Disorders</b>						
Rash	38 (11)	2 (1)	0	7 (2)	0	0
<b>Psychiatric Disorders</b>						
Insomnia	35 (10)	1 (< 1)	0	21 (6)	0	0

\* Represents High Level Term Peripheral Neuropathies NEC

### **Relapsed Multiple Myeloma Randomized Study of Bortezomib Taro vs Dexamethasone**

The safety data described below and in Table 10 reflect exposure to either Bortezomib Taro (n=331) or dexamethasone (n=332) in a study of patients with relapsed multiple myeloma. Bortezomib Taro was administered intravenously at doses of 1.3 mg/m<sup>2</sup> twice weekly for two out of three weeks (21-day cycle). After eight, 21-day cycles patients continued therapy for three, 35-day cycles on a weekly schedule. Duration of treatment was up to 11 cycles (nine months) with a median duration of six cycles (4.1 months). For inclusion in the trial, patients must have had measurable disease and one to three prior therapies. There was no upper age limit for entry. Creatinine clearance could be as low as 20 mL/min and bilirubin levels as high as 1.5 times the upper limit of normal. The overall frequency of adverse events was similar in men and women, and in patients < 65 and ≥ 65 years of age. Most patients were Caucasian [see *Clinical Studies (15.1)*].

Among the 331 Bortezomib Taro treated patients, the most commonly reported (> 20%) adverse reactions overall were nausea (52%), diarrhea (52%), fatigue (39%), peripheral neuropathies (35%), thrombocytopenia (33%), constipation (30%), vomiting (29%), and anorexia (21%). The most commonly reported (> 20%) adverse reaction reported among the 332 patients in the dexamethasone group was fatigue (25%). Eight percent (8%) of patients in the Bortezomib Taro-treated arm experienced a Grade 4 adverse reaction; the most common events were thrombocytopenia (4%) and neutropenia (2%). Nine percent (9%) of dexamethasone treated patients experienced a Grade 4 adverse reaction. All individual dexamethasone-related Grade 4 adverse reactions were less than 1%.

### **Serious Adverse Events (SAEs) and Events Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of Bortezomib Taro vs Dexamethasone**

Serious adverse reactions are defined as any event that results in death, is life-threatening, requires hospitalization or prolongs a current hospitalization, results in a significant disability, or is deemed to be an important medical event.

A total of 80 (24%) patients from the Bortezomib Taro treatment arm experienced a serious adverse event during the study, as did 83 (25%) dexamethasone-treated patients. The most commonly reported serious adverse events in the Bortezomib Taro treatment arm were diarrhea (3%), dehydration, herpes zoster, pyrexia, nausea, vomiting, dyspnea, and thrombocytopenia (2% each). In the dexamethasone treatment group, the most commonly reported serious adverse reactions were pneumonia (4%), hyperglycemia (3%), pyrexia, and psychotic disorder (2% each).

A total of 145 patients, including 84 (25%) of 331 patients in the Bortezomib Taro treatment group and 61 (18%) of 332 patients in the dexamethasone treatment group were discontinued from treatment due to adverse reactions.

Among the 331 Bortezomib Taro treated patients, the most commonly reported adverse reaction leading to discontinuation was peripheral neuropathy (8%). Among the 332 patients in the dexamethasone group, the most commonly reported adverse reactions leading to treatment discontinuation were psychotic disorder and hyperglycemia (2% each).

Four deaths were considered to be Bortezomib Taro-related in this relapsed multiple myeloma study: one case each of cardiogenic shock, respiratory insufficiency, congestive heart failure and cardiac arrest. Four deaths were considered dexamethasone-related: two cases of sepsis, one case of bacterial meningitis, and one case of sudden death at home.

***Most Commonly Reported Adverse Events in the Relapsed Multiple Myeloma Study of Bortezomib Taro vs Dexamethasone***

The most common adverse reactions from the relapsed multiple myeloma study are shown in Table 9. All adverse reactions with incidence  $\geq 10\%$  in the Bortezomib Taro arm are included.

**TABLE 9 - Most Commonly Reported Adverse Reactions ( $\geq 10\%$  in Bortezomib Taro Arm), with Grades 3 and 4 Intensity in Relapsed Multiple Myeloma Study of Bortezomib Taro vs Dexamethasone (n=663)**

Adverse Reactions	Bortezomib Taro (n=331)			Dexamethasone (n=332)		
	All	Grade 3	Grade 4	All	Grade 3	Grade 4
Any adverse reactions	324 (98)	193 (58)	28 (8)	297 (89)	110 (33)	29 (9)
Nausea	172 (52)	8 (2)	0	31 (9)	0	0
Diarrhea NOS	171 (52)	22 (7)	0	36 (11)	2 (< 1)	0
Fatigue	130 (39)	15 (5)	0	82 (25)	8 (2)	0
Peripheral neuropathies*	115 (35)	23 (7)	2 (< 1)	14 (4)	0	1 (< 1)
Thrombocytopenia	109 (33)	80 (24)	12 (4)	11 (3)	5 (2)	1 (< 1)
Constipation	99 (30)	6 (2)	0	27 (8)	1 (< 1)	0
Vomiting NOS	96 (29)	8 (2)	0	10 (3)	1 (< 1)	0
Anorexia	68 (21)	8 (2)	0	8 (2)	1 (< 1)	0
Pyrexia	66 (20)	2 (< 1)	0	21 (6)	3 (< 1)	1 (< 1)
Paresthesia	64 (19)	5 (2)	0	24 (7)	0	0
Anemia NOS	63 (19)	20 (6)	1 (< 1)	21 (6)	8 (2)	0
Headache NOS	62 (19)	3 (< 1)	0	23 (7)	1 (< 1)	0
Neutropenia	58 (18)	37 (11)	8 (2)	1 (< 1)	1 (< 1)	0
Rash NOS	43 (13)	3 (< 1)	0	7 (2)	0	0
Appetite decreased NOS	36 (11)	0	0	12 (4)	0	0
Dyspnea NOS	35 (11)	11 (3)	1 (< 1)	37 (11)	7 (2)	1 (< 1)
Abdominal pain NOS	35 (11)	5(2)	0	7 (2)	0	0
Weakness	34 (10)	10 (3)	0	28 (8)	8 (2)	0

\* Represents High Level Term Peripheral Neuropathies NEC

**Safety Experience from the Phase 2 Open-Label Extension Study in Relapsed Multiple Myeloma**

In the Phase 2 extension study of 63 patients, no new cumulative or new long-term toxicities were observed with prolonged Bortezomib Taro treatment. These patients were treated for a total of 5.3 to 23 months, including time on Bortezomib Taro in the prior Bortezomib Taro study [see Clinical Studies (15.1)].



**Safety Experience from the Phase 3 Open-Label Study of Bortezomib Taro Subcutaneous vs Intravenous in Relapsed Multiple Myeloma**

The safety and efficacy of Bortezomib Taro administered subcutaneously were evaluated in one Phase 3 study at the recommended dose of 1.3 mg/m<sup>2</sup>. This was a randomized, comparative study of Bortezomib Taro subcutaneous vs intravenous in 222 patients with relapsed multiple myeloma. The safety data described below and in Table 10 reflect exposure to either Bortezomib Taro subcutaneous (n=147) or Bortezomib Taro intravenous (n=74) [see *Clinical Studies (15.1)*].

**TABLE 10 - Most Commonly Reported Adverse Reactions (≥ 10%), with Grade 3 and ≥ 4 Intensity in the Relapsed Multiple Myeloma Study (n=221) of Bortezomib Taro Subcutaneous vs Intravenous**

Body System Adverse Reaction	Subcutaneous (n=147)			Intravenous (n= 74)		
	Total n (%)	Toxicity grade, n (%)		Total n (%)	Toxicity grade, n (%)	
		3	≥ 4		3	≥ 4
<b>Blood and Lymphatic System Disorders</b>						
Anemia	28 (19)	8 (5)	0	17 (23)	3 (4)	0
Leukopenia	26 (18)	8 (5)	0	15 (20)	4 (5)	1 (1)
Neutropenia	34 (23)	15 (10)	4 (3)	20 (27)	10 (14)	3 (4)
Thrombocytopenia	44 (30)	7 (5)	5 (3)	25 (34)	7 (9)	5 (7)
<b>Gastrointestinal Disorders</b>						
Diarrhea	28 (19)	1 (1)	0	21 (28)	3 (4)	0
Nausea	24 (16)	0	0	10 (14)	0	0
Vomiting	13 (9)	3 (2)	0	8 (11)	0	0
<b>General Disorders and Administration Site Conditions</b>						
Asthenia	10 (7)	1 (1)	0	12 (16)	4 (5)	0
Fatigue	11 (7)	3 (2)	0	11 (15)	3 (4)	0
Pyrexia	18 (12)	0	0	6 (8)	0	0
<b>Nervous system disorders</b>						
Neuralgia	34 (23)	5 (3)	0	17 (23)	7 (9)	0
Peripheral neuropathies*	55 (37)	8 (5)	1 (1)	37 (50)	10 (14)	1 (1)

Note: Safety population: 147 patients in the subcutaneous treatment group and 74 patients in the intravenous treatment group who received at least one dose of study medication

\*Represents High Level Term Peripheral Neuropathies NEC.

In general, safety data were similar for the subcutaneous and intravenous treatment groups. Differences were observed in the rates of some Grade ≥ 3 adverse reactions. Differences of ≥ 5% were reported in neuralgia (3% subcutaneous vs 9% intravenous), peripheral neuropathies (6% subcutaneous vs 15% intravenous), neutropenia (13% subcutaneous vs 18% intravenous), and thrombocytopenia (8% subcutaneous vs 16% intravenous).

A local reaction was reported in 6% of patients in the subcutaneous group, mostly redness. Only two (1%) patients were reported as having severe events, one case of pruritus and one case of redness. Local reactions led to reduction in injection concentration in one patient and drug discontinuation in one patient. Local reactions resolved in a median of six days.

Dose reductions occurred due to adverse reactions in 31% of patients in the subcutaneous treatment group compared with 43% of the intravenously-treated patients. The most common adverse reactions leading to a dose reduction included peripheral sensory neuropathy (17% in the subcutaneous treatment group compared with 31% in the intravenous treatment group);

and neuralgia (11% in the subcutaneous treatment group compared with 19% in the intravenous treatment group).

**Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of Bortezomib Taro Subcutaneous vs Intravenous**

The incidence of serious adverse reactions was similar for the subcutaneous treatment group (20%) and the intravenous treatment group (19%). The most commonly reported serious adverse reactions in the subcutaneous treatment arm were pneumonia and pyrexia (2% each). In the intravenous treatment group, the most commonly reported serious adverse reactions were pneumonia, diarrhea, and peripheral sensory neuropathy (3% each).

In the subcutaneous treatment group, 27 patients (18%) discontinued study treatment due to an adverse reaction compared with 17 patients (23%) in the intravenous treatment group. Among the 147 subcutaneously-treated patients, the most commonly reported adverse reactions leading to discontinuation were peripheral sensory neuropathy (5%) and neuralgia (5%). Among the 74 patients in the intravenous treatment group, the most commonly reported adverse events leading to treatment discontinuation were peripheral sensory neuropathy (9%) and neuralgia (9%).

Two patients (1%) in the subcutaneous treatment group and one patient (1%) in the intravenous treatment group died due to an adverse reaction during treatment. In the subcutaneous group, the causes of death were one case of pneumonia and one case of sudden death. In the intravenous group, the cause of death was coronary artery insufficiency.

**Safety Experience from the Clinical Trial in Patients with Previously Untreated Mantle Cell Lymphoma**

Table 11 describes safety data from 240 patients with previously untreated mantle cell lymphoma who received Bortezomib Taro (1.3 mg/m<sup>2</sup>) administered intravenously in combination with rituximab (375 mg/m<sup>2</sup>), cyclophosphamide (750 mg/m<sup>2</sup>), doxorubicin (50 mg/m<sup>2</sup>), and prednisone (100 mg/m<sup>2</sup>) (VcR-CAP) in a prospective randomized study.

Infections were reported for 31% of patients in the VcR-CAP arm and 23% of the patients in the comparator (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) arm, including the predominant preferred term of pneumonia (VcR-CAP 8% vs R-CHOP 5%).

**TABLE 11 - Most Commonly Reported Adverse Reactions (≥ 5%) with Grades 3 and ≥ 4 Intensity in the Previously Untreated Mantle Cell Lymphoma Study**

Body System Adverse Reactions	VcR-CAP (n=240)			R-CHOP (n=242)		
	All	Toxicity Grade 3 n (%)	Toxicity Grade ≥ 4 n (%)	All	Toxicity Grade 3 n (%)	Toxicity Grade ≥ 4 n (%)
<b>Blood and Lymphatic System Disorders</b>						
Neutropenia	209 (87)	32 (13)	168 (70)	172 (71)	31 (13)	125 (52)
Leukopenia	116 (48)	34 (14)	69 (29)	87 (36)	39 (16)	27 (11)
Anemia	106 (44)	27 (11)	4 (2)	71 (29)	23 (10)	4 (2)
Thrombocytopenia	172 (72)	59 (25)	76 (32)	42 (17)	9 (4)	3 (1)
Febrile neutropenia	41 (17)	24 (10)	12 (5)	33 (14)	17 (7)	15 (6)
Lymphopenia	68 (28)	25 (10)	36 (15)	28 (12)	15 (6)	2 (1)

Body System Adverse Reactions	VcR-CAP (n=240)			R-CHOP (n=242)		
	All	Toxicity Grade 3 n (%)	Toxicity Grade ≥ 4 n (%)	All	Toxicity Grade 3 n (%)	Toxicity Grade ≥ 4 n (%)
<b>Nervous System Disorders</b>						
Peripheral neuropathy*	71 (30)	17 (7)	1 (< 1)	65 (27)	10 (4)	0
Hypoesthesia	14 (6)	3 (1)	0	13 (5)	0	0
Paresthesia	14 (6)	2 (1)	0	11 (5)	0	0
Neuralgia	25 (10)	9 (4)	0	1 (< 1)	0	0
<b>General Disorders and Administration Site Conditions</b>						
Fatigue	43 (18)	11 (5)	1 (< 1)	38 (16)	5 (2)	0
Pyrexia	48 (20)	7 (3)	0	23 (10)	5 (2)	0
Asthenia	29 (12)	4 (2)	1 (< 1)	18 (7)	1 (< 1)	0
Edema peripheral	16 (7)	1 (< 1)	0	13 (5)	0	0
<b>Gastrointestinal Disorders</b>						
Nausea	54 (23)	1 (< 1)	0	28 (12)	0	0
Constipation	42 (18)	1 (< 1)	0	22 (9)	2 (1)	0
Stomatitis	20 (8)	2 (1)	0	19 (8)	0	1 (< 1)
Diarrhea	59 (25)	11 (5)	0	11 (5)	3 (1)	1 (< 1)
Vomiting	24 (10)	1 (< 1)	0	8 (3)	0	0
Abdominal distension	13 (5)	0	0	4 (2)	0	0
<b>Infections and Infestations</b>						
Pneumonia	20 (8)	8 (3)	5 (2)	11 (5)	5 (2)	3 (1)
<b>Skin and Subcutaneous Tissue Disorders</b>						
Alopecia	31 (13)	1 (< 1)	1 (< 1)	33 (14)	4 (2)	0
<b>Metabolism and Nutrition Disorders</b>						
Hyperglycemia	10 (4)	1 (< 1)	0	17 (7)	10 (4)	0
Decreased appetite	36 (15)	2 (1)	0	15 (6)	1 (< 1)	0
<b>Vascular Disorders</b>						
Hypertension	15 (6)	1 (< 1)	0	3 (1)	0	0
<b>Psychiatric Disorders</b>						
Insomnia	16 (7)	1 (< 1)	0	8 (3)	0	0

Key: R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone;  
VcR-CAP = Bortezomib Taro, rituximab, cyclophosphamide, doxorubicin, and prednisone.

\*Represents High Level Term Peripheral Neuropathies NEC

The incidence of herpes zoster reactivation was 4.6% in the VcR-CAP arm and 0.8% in the R-CHOP arm. Antiviral prophylaxis was mandated by protocol amendment.

The incidences of Grade ≥ 3 bleeding events were similar between the two arms (four patients in the VcR-CAP arm and three patients in the R-CHOP arm). All of the Grade ≥ 3 bleeding events resolved without sequelae in the VcR-CAP arm.

Adverse reactions leading to discontinuation occurred in 8% of patients in VcR-CAP group and 6% of patients in R-CHOP group. In the VcR-CAP group, the most commonly reported adverse reaction leading to discontinuation was peripheral sensory neuropathy (1%; three patients). The most commonly reported adverse reaction leading to discontinuation in the R-CHOP group was febrile neutropenia (< 1%; two patients).

### **Mantle Cell Lymphoma (MCL)**

The safety profile of Bortezomib Taro in 240 MCL patients treated with Bortezomib Taro at 1.3 mg/m<sup>2</sup> in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) vs 242 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] was relatively consistent to that observed in patients with multiple myeloma with main differences described below. Additional adverse drug reactions identified associated with the use of the combination therapy (VcR-CAP) were hepatitis B infection (< 1%) and myocardial ischaemia (1.3%). The similar incidences of these events in both treatment arms, indicated that these adverse drug reactions are not attributable to Bortezomib Taro alone. Notable differences in the MCL patient population as compared to patients in the multiple myeloma studies were a ≥ 5% higher incidence of the haematological adverse reactions (neutropenia, thrombocytopenia, leukopenia, anemia, lymphopenia), peripheral sensory neuropathy, hypertension, pyrexia, pneumonia, stomatitis, and hair disorders.

Adverse drug reactions identified as those with a ≥ 1% incidence, similar or higher incidence in the VcR-CAP arm and with at least a possible or probable causal relationship to the components of the VcR-CAP arm, are listed in Table 12 below. Also included are adverse drug reactions identified in the VcR-CAP arm that were considered by investigators to have at least a possible or probable causal relationship to Bortezomib Taro based on historical data in the multiple myeloma studies.

Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as: Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000), Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Table 12 has been generated using Version 16 of the MedDRA.

**TABLE 12: Adverse Reactions in Patients with Mantle Cell Lymphoma Treated with VcR-CAP in a Clinical Trial**

<b>Body System</b>	<b>Incidence</b>	<b>Adverse reaction</b>
Infections and infestations	Very Common	Pneumonia*
	Common	Sepsis (inc septic shock)*, Herpes zoster (inc disseminated & ophthalmic), Herpes virus infection*, Bacterial infections*, Upper/lower respiratory tract infection*, Fungal infection*, Herpes simplex*
	Uncommon	Hepatitis B, Infection*, Bronchopneumonia
Blood and Lymphatic System Disorders	Very Common	Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anemia*, Lymphopenia*
	Uncommon	Pancytopenia*
	Common	Hypersensitivity*
Immune System Disorders	Anaphylactic reaction	Anaphylactic reaction
Metabolism and Nutrition Disorders	Very Common	Decreased appetite
	Common	Hypokalaemia*, Blood glucose abnormal*, Hyponatraemia*, Diabetes mellitus*, Fluid retention
	Uncommon	Tumour lysis syndrome
Psychiatric Disorders	Common	Sleep disorders and disturbances*

<b>Body System</b>	<b>Incidence</b>	<b>Adverse reaction</b>
Nervous System Disorders	Very Common	Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia*
	Common	Neuropathies*, Motor neuropathy*, Loss of consciousness (inc syncope), Encephalopathy*, Peripheral sensorimotor neuropathy, Dizziness*, Dysgeusia*, Autonomic neuropathy
	Uncommon	Autonomic nervous system imbalance
Eye Disorders	Common	Vision abnormal*
Ear and Labyrinth Disorders	Common	Dysacusis (inc tinnitus)*
	Uncommon	Vertigo*, Hearing impaired (up to and inc deafness)
Cardiac Disorders	Common	Cardiac fibrillation (inc atrial), Arrhythmia*, Cardiac failure (inc left and right ventricular)*, Myocardial ischaemia, Ventricular dysfunction*
	Uncommon	Cardiovascular disorder (inc cardiogenic shock)
Vascular Disorders	Common	Hypertension*, Hypotension*, Orthostatic hypotension
Respiratory, Thoracic and Mediastinal Disorders	Common	Dyspnoea*, Cough*, Hiccups
	Uncommon	Acute respiratory distress syndrome, Pulmonary embolism, Pneumonitis, Pulmonary hypertension, Pulmonary oedema (inc acute)
Gastrointestinal Disorders	Very Common	Nausea and vomiting symptoms*, Diarrhea*, Stomatitis*, Constipation
	Common	Gastrointestinal haemorrhage (inc mucosal)*, Abdominal distension, Dyspepsia, Oropharyngeal pain*, Gastritis*, Oral ulceration*, Abdominal discomfort, Dysphagia, Gastrointestinal inflammation*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder*
	Uncommon	Colitis (inc clostridium difficile)*
Hepatobiliary Disorders	Common	Hepatotoxicity (inc liver disorder)
	Uncommon	Hepatic failure
Skin and Subcutaneous Tissue Disorders	Very Common	Hair disorder*
	Common	Pruritus*, Dermatitis*, Rash*
Musculoskeletal and Connective Tissue Disorders	Common	Muscle spasms*, Musculoskeletal pain*, Pain in extremity
Renal and Urinary Disorders	Common	Urinary tract infection*
General Disorders and Administration Site Conditions	Very Common	Pyrexia*, Fatigue, Asthenia
	Common	Oedema (inc peripheral), Chills, Injection site reaction*, Malaise*
Investigations	Common	Hyperbilirubinaemia*, Protein analyses abnormal*, Weight decreased, Weight increased

\*Grouping of more than one MedDRA Preferred Term.

**Integrated Summary of Safety (Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma)**

Safety data from Phase 2 and 3 studies of single agent Bortezomib Taro 1.3 mg/m<sup>2</sup>/dose twice weekly for 2 weeks followed by a ten-day rest period in 1163 patients with previously treated multiple myeloma (n=1008) and previously treated mantle cell lymphoma (n=155) were integrated and tabulated. This analysis does not include data from Phase 3 open label study of Bortezomib Taro subcutaneous vs intravenous in relapsed multiple myeloma. In the integrated studies, the safety profile of Bortezomib Taro was similar in patients with multiple myeloma and mantle cell lymphoma [see *Clinical Studies (15)*].

In the integrated analysis, the most commonly reported (> 20%) adverse reactions were nausea (49%), diarrhea (46%), asthenic conditions including fatigue (41%) and weakness (11%), peripheral neuropathies (38%), thrombocytopenia (32%), vomiting (28%), constipation (25%), and pyrexia (21%). Eleven percent (11%) of patients experienced at least one episode of ≥ Grade 4 toxicity, most commonly thrombocytopenia (4%) and neutropenia (2%).

In the Phase 2 relapsed multiple myeloma clinical trials of Bortezomib Taro administered intravenously, local skin irritation was reported in 5% of patients, but extravasation of Bortezomib Taro was not associated with tissue damage.

***Serious Adverse Reactions (SAEs) and Reactions Leading to Treatment Discontinuation in the Integrated Summary of Safety***

A total of 26% of patients experienced a serious adverse reaction during the studies. The most commonly reported serious adverse reactions included diarrhea, vomiting and pyrexia (3% each), nausea, dehydration, and thrombocytopenia (2% each) and pneumonia, dyspnea, peripheral neuropathies, and herpes zoster (1% each).

Adverse reactions leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), and fatigue, thrombocytopenia, and diarrhea (2% each).

In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis.

***Most Commonly Reported Adverse Reactions in the Integrated Summary of Safety***

The most common adverse reactions are shown in Table 13. All adverse reactions occurring at ≥ 10% are included. In the absence of a randomized comparator arm, it is often not possible to distinguish between adverse reactions that are drug-caused and those that reflect the patient’s underlying disease. Please see the discussion of specific adverse reactions that follows.

**TABLE 13 - Most Commonly Reported (≥ 10% Overall) Adverse Reactions in Integrated Analyses of Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma Studies Using the 1.3 mg/m<sup>2</sup> Dose (n=1163)**

Adverse Reactions	All Patients (n=1163)		Multiple Myeloma (n=1008)		Mantle Cell Lymphoma (n=155)	
	All	≥ Grade 3	All	≥ Grade 3	All	≥ Grade 3
Nausea	567 (49)	36 (3)	511 (51)	32 (3)	56 (36)	4 (3)
Diarrhea NOS	530 (46)	83 (7)	470 (47)	72 (7)	60 (39)	11 (7)
Fatigue	477 (41)	86 (7)	396 (39)	71 (7)	81 (52)	15 (10)

Adverse Reactions	All Patients (n=1163)		Multiple Myeloma (n=1008)		Mantle Cell Lymphoma (n=155)	
	All	≥ Grade 3	All	≥ Grade 3	All	≥ Grade 3
Peripheral neuropathies*	443 (38)	129 (11)	359 (36)	110 (11)	84 (54)	19 (12)
Thrombocytopenia	369 (32)	295 (25)	344 (34)	283 (28)	25 (16)	12 (8)
Vomiting NOS	321 (28)	44 (4)	286 (28)	40 (4)	35 (23)	4 (3)
Constipation	296 (25)	17 (1)	244 (24)	14 (1)	52 (34)	3 (2)
Pyrexia	249 (21)	16 (1)	233 (23)	15 (1)	16 (10)	1 (< 1)
Anorexia	227 (20)	19 (2)	205 (20)	16 (2)	22 (14)	3 (2)
Anemia NOS	209 (18)	65 (6)	190 (19)	63 (6)	19 (12)	2 (1)
Headache NOS	175 (15)	8 (< 1)	160 (16)	8 (< 1)	15 (10)	0
Neutropenia	172 (15)	121 (10)	164 (16)	117 (12)	8 (5)	4 (3)
Rash NOS	156 (13)	8 (< 1)	120 (12)	4 (< 1)	36 (23)	4 (3)
Paresthesia	147 (13)	9 (< 1)	136 (13)	8 (< 1)	11 (7)	1 (< 1)
Dizziness (excl vertigo)	129 (11)	13 (1)	101 (10)	9 (< 1)	28 (18)	4 (3)
Weakness	124 (11)	31 (3)	106 (11)	28 (3)	18 (12)	3 (2)

\*Represents High Level Term Peripheral Neuropathies NEC

### **Description of Selected Adverse Reactions from the Integrated Phase 2 and 3 Relapsed Multiple Myeloma and Phase 2 Relapsed Mantle Cell Lymphoma Studies**

#### **Gastrointestinal Toxicity**

A total of 75% of patients experienced at least one gastrointestinal disorder. The most common gastrointestinal disorders included nausea, diarrhea, constipation, vomiting, and appetite decreased. Other gastrointestinal disorders included dyspepsia and dysgeusia. Grade 3 adverse reactions occurred in 14% of patients; ≥ Grade 4 adverse reactions were rare (≤ 1%). Gastrointestinal adverse reactions were considered serious in 7% of patients. Four percent (4%) of patients discontinued due to a gastrointestinal adverse reactions. Nausea was reported more often in patients with multiple myeloma (51%) compared to patients with mantle cell lymphoma (36%).

#### **Thrombocytopenia**

Across the studies, Bortezomib Taro-associated thrombocytopenia was characterized by a decrease in platelet count during the dosing period (days 1 to 11) and a return toward baseline during the ten-day rest period during each treatment cycle. Overall, thrombocytopenia was reported in 32% of patients. Thrombocytopenia was Grade 3 in 22%, ≥ Grade 4 in 4%, and serious in 2% of patients, and the reaction resulted in Bortezomib Taro discontinuation in 2% of patients [see *Warnings and Precautions (7.7)*]. Thrombocytopenia was reported more often in patients with multiple myeloma (34%) compared to patients with mantle cell lymphoma (16%). The incidence of ≥Grade 3 thrombocytopenia also was higher in patients with multiple myeloma (28%) compared to patients with mantle cell lymphoma (8%).

#### **Peripheral Neuropathy**

Overall, peripheral neuropathies occurred in 38% of patients. Peripheral neuropathy was Grade 3 for 11% of patients and ≥ Grade 4 for < 1% of patients. Eight percent (8%) of patients discontinued Bortezomib Taro due to peripheral neuropathy. The incidence of peripheral neuropathy was higher among patients with mantle cell lymphoma (54%) compared to patients with multiple myeloma (36%).

In the Bortezomib Taro vs dexamethasone Phase 3 relapsed multiple myeloma study, among the 62 Bortezomib Taro-treated patients who experienced  $\geq$  Grade 2 peripheral neuropathy and had dose adjustments, 48% had improved or resolved with a median of 3.8 months from first onset.

In the Phase 2 relapsed multiple myeloma studies, among the 30 patients who experienced Grade 2 peripheral neuropathy resulting in discontinuation or who experienced  $\geq$  Grade 3 peripheral neuropathy, 73% reported improvement or resolution with a median time of 47 days to improvement of one grade or more from the last dose of Bortezomib Taro.

### **Hypotension**

The incidence of hypotension (postural hypotension, orthostatic hypotension and hypotension NOS) was 8% in patients treated with Bortezomib Taro. Hypotension was Grade 1 or 2 in the majority of patients and Grade 3 in 2% and  $\geq$  Grade 4 in  $<$  1%. Two percent (2%) of patients had hypotension reported as a serious adverse reaction, and 1% discontinued due to hypotension. The incidence of hypotension was similar in patients with multiple myeloma (8%) and those with mantle cell lymphoma (9%). In addition,  $<$  1% of patients experienced hypotension associated with a syncopal reaction.

### **Neutropenia**

Neutrophil counts decreased during the Bortezomib Taro dosing period (days 1 to 11) and returned toward baseline during the ten-day rest period during each treatment cycle. Overall, neutropenia occurred in 15% of patients and was Grade 3 in 8% of patients and  $\geq$  Grade 4 in 2%.

Neutropenia was reported as a serious adverse reaction in  $<$  1% of patients and  $<$  1% of patients discontinued due to neutropenia. The incidence of neutropenia was higher in patients with multiple myeloma (16%) compared to patients with mantle cell lymphoma (5%). The incidence of  $\geq$  Grade 3 neutropenia also was higher in patients with multiple myeloma (12%) compared to patients with mantle cell lymphoma (3%).

### **Asthenic Conditions (Fatigue, Malaise, Weakness, Asthenia)**

Asthenic conditions were reported in 54% of patients.

Fatigue was reported as Grade 3 in 7% and  $\geq$  Grade 4 in  $<$  1% of patients. Asthenia was reported as Grade 3 in 2% and  $\geq$  Grade 4 in  $<$  1% of patients. Two percent (2%) of patients discontinued treatment due to fatigue and  $<$  1% due to weakness and asthenia. Asthenic conditions were reported in 53% of patients with multiple myeloma and 59% of patients with mantle cell lymphoma.

### **Pyrexia**

Pyrexia ( $>$  38°C) was reported as an adverse reaction for 21% of patients. The reaction was Grade 3 in 1% and  $\geq$  Grade 4 in  $<$  1%. Pyrexia was reported as a serious adverse reaction in 3% of patients and led to Bortezomib Taro discontinuation in  $<$  1% of patients. The incidence of pyrexia was higher among patients with multiple myeloma (23%) compared to patients with mantle cell lymphoma (10%). The incidence of  $\geq$  Grade 3 pyrexia was 1% in patients with multiple myeloma and  $<$  1% in patients with mantle cell lymphoma.

### **Herpes Virus Infection**

Consider using antiviral prophylaxis in subjects being treated with Bortezomib Taro. In the randomized studies in previously untreated and relapsed multiple myeloma, herpes zoster reactivation was more common in subjects treated with Bortezomib Taro (ranging between 6-11%) than in the control groups (3-4%). Herpes simplex was seen in 1-3% in subjects treated with Bortezomib Taro and 1-3% in the control groups. In the previously untreated multiple myeloma study, herpes zoster virus reactivation in the Bortezomib Taro, melphalan and



prednisone arm was less common in subjects receiving prophylactic antiviral therapy (3%) than in subjects who did not receive prophylactic antiviral therapy (17%).

### **Retreatment in Relapsed Multiple Myeloma**

A single-arm trial was conducted in 130 patients with relapsed multiple myeloma to determine the efficacy and safety of retreatment with intravenous Bortezomib Taro. The safety profile of patients in this trial is consistent with the known safety profile of Bortezomib Taro -treated patients with relapsed multiple myeloma as demonstrated in Tables 10, 11, and 13; no cumulative toxicities were observed upon retreatment. The most common adverse drug reaction was thrombocytopenia which occurred in 52% of the patients. The incidence of  $\geq$  Grade 3 thrombocytopenia was 24%. Peripheral neuropathy occurred in 28% of patients, with the incidence of  $\geq$  Grade 3 peripheral neuropathy reported at 6%.

The incidence of serious adverse reactions was 12.3%. The most commonly reported serious adverse reactions were thrombocytopenia (3.8%), diarrhea (2.3%), and herpes zoster and pneumonia (1.5% each).

Adverse reactions leading to discontinuation occurred in 13% of patients. The reasons for discontinuation included peripheral neuropathy (5%) and diarrhea (3%).

Two deaths considered to be Bortezomib Taro-related occurred within 30 days of the last Bortezomib Taro dose; one in a patient with cerebrovascular accident and one in a patient with sepsis.

### **Additional Serious Adverse Events from Clinical Studies**

The following clinically important serious adverse reactions that are not described above have been reported in clinical trials in patients treated with Bortezomib Taro administered as monotherapy or in combination with other chemotherapeutics. These studies were conducted in patients with hematological malignancies and in solid tumors.

***Blood and Lymphatic System Disorders:*** Anemia, disseminated intravascular coagulation, febrile neutropenia, lymphopenia, leukopenia

***Cardiac Disorders:*** Angina pectoris, atrial fibrillation aggravated, atrial flutter, bradycardia, sinus arrest, cardiac amyloidosis, complete atrioventricular block, myocardial ischemia, myocardial infarction, pericarditis, pericardial effusion, *Torsades de pointes*, ventricular tachycardia

***Ear and Labyrinth Disorders:*** Hearing impaired, vertigo

***Eye Disorders:*** Diplopia and blurred vision, conjunctival infection, irritation

***Gastrointestinal Disorders:*** Abdominal pain, ascites, dysphagia, fecal impaction, gastroenteritis, gastritis hemorrhagic, hematemesis, hemorrhagic duodenitis, ileus paralytic, large intestinal obstruction, paralytic intestinal obstruction, peritonitis, small intestinal obstruction, large intestinal perforation, stomatitis, melena, pancreatitis acute, oral mucosal petechiae, gastroesophageal reflux

***General Disorders and Administration Site Conditions:*** Chills, edema, edema peripheral, injection site erythema, neuralgia, injection site pain, irritation, malaise, phlebitis

***Hepatobiliary Disorders:*** Cholestasis, hepatic hemorrhage, hyperbilirubinemia, portal vein thrombosis, hepatitis, liver failure.

***Immune System Disorders:*** Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, angioedema, laryngeal edema

***Infections and Infestations:*** Aspergillosis, bacteremia, bronchitis, urinary tract infection, herpes viral infection, listeriosis, nasopharyngitis, pneumonia, respiratory tract infection, septic shock, toxoplasmosis, oral candidiasis, sinusitis, catheter-related infection

***Injury, Poisoning and Procedural Complications:*** Catheter-related complication, skeletal fracture, subdural hematoma

***Investigations:*** Weight decreased

***Metabolism and Nutrition Disorders:*** Dehydration, hypocalcemia, hyperuricemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia

***Musculoskeletal and Connective Tissue Disorders:*** Arthralgia, back pain, bone pain, myalgia, pain in extremity

***Nervous System Disorders:*** Ataxia, coma, dizziness, dysarthria, dysesthesia, dysautonomia, encephalopathy, cranial palsy, grand mal convulsion, headache, hemorrhagic stroke, motor dysfunction, neuralgia, spinal cord compression, paralysis, postherpetic neuralgia, transient ischemic attack

***Psychiatric Disorders:*** Agitation, anxiety, confusion, insomnia, mental status change, psychotic disorder, suicidal ideation

***Renal and Urinary Disorders:*** Calculus renal, bilateral hydronephrosis, bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, renal failure (acute and chronic), glomerular nephritis proliferative

***Respiratory, Thoracic and Mediastinal Disorders:*** Acute respiratory distress syndrome, aspiration pneumonia, atelectasis, chronic obstructive airways disease exacerbated, cough, dysphagia, dyspnea, dyspnea exertional, epistaxis, hemoptysis, hypoxia, lung infiltration, pleural effusion, pneumonitis, respiratory distress, pulmonary hypertension

***Skin and Subcutaneous Tissue Disorders:*** Urticaria, face edema, rash (which may be pruritic), leukocytoclastic vasculitis, pruritus

***Vascular Disorders:*** Cerebrovascular accident, cerebral hemorrhage, deep venous thrombosis, hypertension, peripheral embolism, pulmonary embolism, pulmonary hypertension

## **Mantle Cell Lymphoma**

Antiviral prophylaxis was administered to 137 of 240 patients (57%) in the VcR-CAP arm. The incidence of herpes zoster among patients in the VcR-CAP arm was 10.7% for patients not administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis (see section 7.13).

### **Hepatitis B Virus (HBV) Reactivation and Infection**

HBV infection with fatal outcomes occurred in 0.8% (n=2) of patients in the non-Bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP ) and 0.4% (n=1) of patients receiving Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP). The overall incidence of hepatitis B infections was similar in patients treated with VcR-CAP or with R-CHOP (0.8% vs 1.2% respectively).

In study LYM-3002 in which Bortezomib Taro was administered with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CAP), the incidence of peripheral neuropathy in the combination regimens is presented in the table below:

**TABLE 14: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment discontinuation due to peripheral neuropathy**

	VcR-CAP (n=240)	R-CHOP (n=242)
Incidence of PN (%)		
All Grade PN	30	29
≥ Grade 2 PN	18	9
≥ Grade 3 PN	8	4
Discontinuation due to PN (%)	2	< 1

VcR-CAP=Bortezomib Taro, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy

Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy

### **Elderly MCL Patients**

42.9% and 10.4% of patients in the VcR-CAP arm were in the range 65-74 years and ≥ 75 years of age, respectively. Although in patients aged ≥ 75 years, both VcR-CAP and R-CHOP were less tolerated, the serious adverse event rate in the VcR-CAP groups was 68%, compared to 42% in the R-CHOP group.

### **8.2 Postmarketing Experience**

The following adverse drug events have been identified from the worldwide post-marketing experience with Bortezomib Taro. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

**Cardiac Disorders:** Cardiac tamponade

**Ear and Labyrinth Disorders:** Deafness bilateral

**Eye Disorders:** Optic neuropathy, blindness, chalazion/blepharitis

**Gastrointestinal Disorders:** Ischemic colitis

**Infections and Infestations:** Progressive multifocal leukoencephalopathy (PML), ophthalmic herpes, herpes meningoencephalitis

**Nervous System Disorders:** Posterior reversible encephalopathy syndrome (PRES, formerly RPLS), Guillain-Barre syndrome, demyelinating polyneuropathy

**Respiratory, Thoracic and Mediastinal Disorders:** Acute diffuse infiltrative pulmonary disease

**Skin and Subcutaneous Tissue Disorders:** Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute febrile neutrophilic dermatosis (Sweet's syndrome)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form:

<https://sideeffects.health.gov.il>

## 9. **DRUG INTERACTIONS**

Bortezomib is a substrate of cytochrome P450 enzyme 3A4, 2C19 and 1A2.

### 9.1 **Effects of Other Drugs on Bortezomib Taro**

#### Strong CYP3A4 Inducers

Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [*see Clinical Pharmacology (13.3)*] which may decrease its efficacy. Avoid coadministration with strong CYP3A4 inducers.

#### Strong CYP3A4 Inhibitors

Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [*see Clinical Pharmacology (13.3)*] which may increase the risk of bortezomib toxicities. Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combination with strong CYP3A4 inhibitors.

### 9.2 **Drugs Without Clinically Significant Interactions with Bortezomib Taro**

No clinically significant drug interactions have been observed when Bortezomib Taro was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [*see Clinical Pharmacology (13.3)*].

During clinical trials, hypoglycemia and hyperglycemia were uncommonly and commonly reported in diabetic patients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving Bortezomib Taro treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetics.

## 10. **USE IN SPECIFIC POPULATIONS**

### 10.1 **Pregnancy**

#### Risk Summary

Based on its mechanism of action [*see Clinical Pharmacology (13.1)*] and findings in animals, Bortezomib Taro can cause fetal harm when administered to a pregnant woman. There are no studies with the use of Bortezomib Taro in pregnant women to inform drug-associated risks. Bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (*see Data*). Advise pregnant women of the potential risk to the fetus.

Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

#### Data

##### *Animal Data*

Bortezomib was not teratogenic in nonclinical developmental toxicity studies in rats and rabbits at the highest dose tested (0.075 mg/kg; 0.5 mg/m<sup>2</sup> in the rat and 0.05 mg/kg; 0.6 mg/m<sup>2</sup> in the rabbit) when administered during organogenesis. These dosages are approximately half the clinical dose of 1.3 mg/m<sup>2</sup> based on body surface area.

Bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (approximately 0.5 times the clinical dose of 1.3 mg/m<sup>2</sup> based on body surface area).

Pregnant rabbits given bortezomib during organogenesis at a dose of 0.05 mg/kg (0.6 mg/m<sup>2</sup>) experienced significant postimplantation loss and decreased number of live fetuses. Live fetuses from these litters also showed significant decreases in fetal weight.

## **10.2 Lactation**

### Risk Summary

There are no data on the presence of bortezomib or its metabolites in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. Because many drugs are excreted in human milk and because the potential for serious adverse reactions in a breastfed child from Bortezomib Taro is unknown, advise nursing women not to breastfeed during treatment with Bortezomib Taro and for two months after treatment.

## **10.3 Females and Males of Reproductive Potential**

Based on its mechanism of action and findings in animals, Bortezomib Taro can cause fetal harm when administered to a pregnant woman [*see Use in Specific Populations (10.1)*].

### Pregnancy Testing

Conduct pregnancy testing in females of reproductive potential prior to initiating Bortezomib Taro treatment.

### Contraception

#### *Females*

Advise females of reproductive potential to use effective contraception during treatment with Bortezomib Taro and for seven months after the last dose.

#### *Males*

Males with female partners of reproductive potential should use effective contraception during treatment with Bortezomib Taro and for four months after the last dose.

### Infertility

Based on the mechanism of action and findings in animals, Bortezomib Taro may have an effect on either male or female fertility [*see Nonclinical Toxicology (14.1)*].

## **10.4 Pediatric Use**

Safety and effectiveness have not been established in pediatric patients.

The activity and safety of Bortezomib Taro in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies (pre-B cell ALL 77%, 16% with T-cell ALL, and 7% T-cell lymphoblastic lymphoma (LL)), all of whom relapsed within 36 months of initial diagnosis in a single-arm multicenter, nonrandomized cooperative group trial. An effective reinduction multiagent chemotherapy regimen was administered in three blocks. Block 1 included vincristine, prednisone, doxorubicin and pegaspargase; block 2 included cyclophosphamide, etoposide and methotrexate; block 3 included high dose cytosine arabinoside and asparaginase.

Bortezomib Taro was administered at a dose of 1.3 mg/m<sup>2</sup> as a bolus intravenous injection on days 1, 4, 8, and 11 of block 1 and days 1, 4, and 8 of block 2. There were 140 patients with ALL or LL enrolled and evaluated for safety. The median age was ten years (range: 1 to 26), 57% were male, 70% were white, 14% were black, 4% were Asian, 2% were American Indian/Alaska Native, 1% were Pacific Islander.

The activity was evaluated in a pre-specified subset of the first 60 evaluable patients enrolled on the study with pre-B ALL  $\leq 21$  years and relapsed  $< 36$  months from diagnosis. The complete remission (CR) rate at day 36 was compared to that in a historical control set of patients who had received the identical backbone therapy without Bortezomib Taro. There was no evidence that the addition of Bortezomib Taro had any impact on the CR rate.

No new safety concerns were observed when Bortezomib Taro was added to a chemotherapy backbone regimen as compared with a historical control group in which the backbone regimen was given without Bortezomib Taro.

The BSA-normalized clearance of bortezomib in pediatric patients was similar to that observed in adults.

### **10.5 Geriatric Use**

Of the 669 patients enrolled in the relapsed multiple myeloma study, 245 (37%) were 65 years of age or older: 125 (38%) on the Bortezomib Taro arm and 120 (36%) on the dexamethasone arm. Median time to progression and median duration of response for patients  $\geq 65$  were longer on Bortezomib Taro compared to dexamethasone [5.5 mo vs 4.3 mo, and 8.0 mo vs 4.9 mo, respectively]. On the Bortezomib Taro arm, 40% (n=46) of evaluable patients aged  $\geq 65$  experienced response (CR+PR) vs 18% (n=21) on the dexamethasone arm. The incidence of Grade 3 and 4 events was 64%, 78% and 75% for Bortezomib Taro patients  $\leq 50$ , 51-64 and  $\geq 65$  years old, respectively [see *Adverse Events (8.1)*; *Clinical Studies (15)*].

No overall differences in safety or effectiveness were observed between patients  $\geq$  age 65 and younger patients receiving Bortezomib Taro; but greater sensitivity of some older individuals cannot be ruled out.

### **10.6 Renal Impairment**

No starting dosage adjustment of Bortezomib Taro is recommended for patients with renal impairment. In patients requiring dialysis, Bortezomib Taro should be administered after the dialysis procedure [see *Clinical Pharmacology (13.3)*]

### **10.7 Patients with Hepatic Impairment**

No starting dosage adjustment of Bortezomib Taro is recommended for patients with mild hepatic impairment (total bilirubin  $\leq 1$ x ULN and AST  $>$  ULN, or total bilirubin  $> 1$  to 1.5x ULN and any AST). The exposure of bortezomib is increased in patients with moderate (total bilirubin  $\geq 1.5$  to 3x ULN and any AST) and severe (total bilirubin  $> 3$ x ULN and any AST) hepatic impairment. Reduce the starting dose in patients with moderate or severe hepatic impairment [see *Dosage and Administration (4.6)*, *Clinical Pharmacology (13.3)*].

### **10.8 Patients with Diabetes**

During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving Bortezomib Taro treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.

## 11. OVERDOSAGE

There is no known specific antidote for Bortezomib Taro overdose. In humans, fatal outcomes following the administration of more than twice the recommended therapeutic dose have been reported, which were associated with the acute onset of symptomatic hypotension (7.2) and thrombocytopenia (7.7). In the event of an overdose, the patient's vital signs should be monitored and appropriate supportive care given.

Studies in monkeys and dogs showed that intravenous bortezomib doses as low as two times the recommended clinical dose on a mg/m<sup>2</sup> basis were associated with increases in heart rate, decreases in contractility, hypotension, and death. In dog studies, a slight increase in the corrected QT interval was observed at doses resulting in death. In monkeys, doses of 3.0 mg/m<sup>2</sup> and greater (approximately twice the recommended clinical dose) resulted in hypotension starting at one-hour postadministration, with progression to death in 12 to 14 hours following drug administration.


## 12. DESCRIPTION

Bortezomib Taro 3.5 mg powder for solution for injection, a proteasome inhibitor, contains bortezomib, which is an antineoplastic agent.

Bortezomib is a modified dipeptidyl boronic acid.

The chemical name for bortezomib, the monomeric boronic acid, is [(1R)-3-methyl-1-[[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid.

Bortezomib has the following chemical structure:



The molecular weight is 384.24. The molecular formula is C<sub>19</sub>H<sub>25</sub>BN<sub>4</sub>O<sub>4</sub>. The solubility of bortezomib, as the monomeric boronic acid, in water is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5.

Bortezomib Taro 3.5 mg is available for intravenous injection or subcutaneous use. Each single use vial contains 3.5 mg of bortezomib as a sterile lyophilized powder. It also contains the inactive ingredient: 35 mg mannitol. The product is provided as a mannitol boronic ester which, in reconstituted form, consists of the mannitol ester in equilibrium with its hydrolysis product, the monomeric boronic acid. The drug substance exists in its cyclic anhydride form as a trimeric boroxine.

## 13. CLINICAL PHARMACOLOGY

### 13.1 Mechanism of Action

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect

multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.

### 13.2 Pharmacodynamics

Following twice weekly administration of 1 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup> bortezomib doses, the maximum inhibition of 20S proteasome activity (relative to baseline) in whole blood was observed five minutes after drug administration. Comparable maximum inhibition of 20S proteasome activity was observed between 1 and 1.3 mg/m<sup>2</sup> doses. Maximal inhibition ranged from 70% to 84% and from 73% to 83% for the 1 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup> dose regimens, respectively.

### 13.3 Pharmacokinetics

Following intravenous administration of 1 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup> doses, the mean maximum plasma concentrations of bortezomib (C<sub>max</sub>) after the first dose (Day 1) were 57 and 112 ng/mL, respectively. When administered twice weekly, the mean maximum observed plasma concentrations ranged from 67 to 106 ng/mL for the 1 mg/m<sup>2</sup> dose and 89 to 120 ng/mL for the 1.3mg/m<sup>2</sup> dose.

Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m<sup>2</sup> dose to patients with multiple myeloma, the total systemic exposure after repeat dose administration (AUC<sub>last</sub>) was equivalent for subcutaneous and intravenous administration. The AUC<sub>last</sub> geometric mean ratio (90% confidence interval) was 0.99 (0.80 to 1.23). The C<sub>max</sub> after subcutaneous administration (20.4 ng/mL) was lower than intravenous administration (223 ng/mL) with repeat dose administration.

**Distribution:** The mean distribution volume of bortezomib ranged from approximately 498 to 1884 L/m<sup>2</sup> following single- or repeat-dose administration of 1 mg/m<sup>2</sup> or 1.3 mg/m<sup>2</sup> to patients with multiple myeloma. The binding of bortezomib to human plasma proteins averaged 83% over the concentration range of 100 to 1000 ng/mL.

**Elimination:** The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m<sup>2</sup> dose and 76 to 108 hours after the 1.3 mg/m<sup>2</sup> dose. The mean total body clearances were 102 and 112 L/h following the first dose for doses of 1 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup>, respectively, and ranged from 15 to 32 L/h following subsequent doses for doses of 1 and 1.3 mg/m<sup>2</sup>, respectively.

**Metabolism:** Bortezomib is primarily oxidatively metabolized to several inactive metabolites in vitro via cytochrome P450 (CYP) enzymes 3A4, CYP2C19, and CYP1A2, and to a lesser extent by CYP2D6 and CYP2C9.

**Excretion:** The pathways of elimination of bortezomib have not been characterized in humans.

#### **Specific Populations**

No clinically significant differences in the pharmacokinetics of bortezomib were observed based on age, sex, or renal impairment (including patients administered bortezomib after dialysis). The effect of race on bortezomib pharmacokinetics is unknown.



## ***Hepatic Impairment***

Following administration of bortezomib doses ranging from 0.5 to 1.3 mg/m<sup>2</sup>, mild (total bilirubin ≤1x ULN and AST > ULN, or total bilirubin >1 to 1.5x ULN and any AST) hepatic impairment did not alter dose-normalized bortezomib AUC when compared to patients with normal hepatic function. Dose normalized mean bortezomib AUC increased by approximately 60% in patients with moderate (total bilirubin >1.5 to 3x ULN and any AST) or severe (total bilirubin >3x ULN and any AST) hepatic impairment. A lower starting dose is recommended in patients with moderate or severe hepatic impairment.

## ***Renal Impairment***

A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCl) into the following groups: Normal (CrCl ≥60 mL/min/1.73 m<sup>2</sup>, n=12), Mild (CrCl=40-59 mL/min/1.73 m<sup>2</sup>, n=10), Moderate (CrCl=20-39 mL/min/1.73 m<sup>2</sup>, n=9), and Severe (CrCl < 20 mL/min/1.73 m<sup>2</sup>, n=3). A group of dialysis patients who were dosed after dialysis was also included in the study (n=8). Patients were administered intravenous doses of 0.7 to 1.3 mg/ m<sup>2</sup> of bortezomib twice weekly. Exposure of bortezomib (dose-normalized AUC and C<sub>max</sub>) was comparable among all the groups [See Use in Specific Populations (10.6)].

## **Drug Interaction Studies**

### *Clinical Studies*

No clinically significant differences in bortezomib pharmacokinetics were observed when coadministered with dexamethasone (weak CYP3A4 inducer), omeprazole (strong CYP2C19 inhibitor), or melphalan in combination with prednisone.

*In vitro* studies indicate that bortezomib is a weak inhibitor of the cytochrome P450 (CYP) isozymes 1A2, 2C9, 2C19, 2D6 and 3A4. Based on the limited contribution (7%) of CYP2D6 to the metabolism of bortezomib, the CYP2D6 poor metaboliser phenotype is not expected to affect the overall disposition of bortezomib.

A drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 35% (CI90% [1.032 to 1.772]) based on data from 12 patients. Therefore, patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir).

In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 17 patients.

A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC reduction of 45% based on data from six patients. Therefore, the concomitant use of bortezomib with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital and St. John's Wort) is not recommended, as efficacy may be reduced.

In the same drug-drug interaction study assessing the effect of dexamethasone, a weaker CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from seven patients.

### *Strong CYP3A4 Inhibitor*

Coadministration with ketoconazole (strong CYP3A4 inhibitor) increased bortezomib exposure by 35%.

#### *Strong CYP3A4 Inducer*

Coadministration with rifampin (strong CYP3A4 inducer) decreased bortezomib exposure by approximately 45%.

#### *In Vitro Studies*

Bortezomib may inhibit CYP2C19 activity and increase exposure to drugs that are substrates for this enzyme.

## **14. NONCLINICAL TOXICOLOGY**

### **14.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Carcinogenicity studies have not been conducted with bortezomib.

Bortezomib showed clastogenic activity (structural chromosomal aberrations) in the in vitro chromosomal aberration assay using Chinese hamster ovary cells. Bortezomib was not genotoxic when tested in the in vitro mutagenicity assay (Ames test) and in vivo micronucleus assay in mice.

Fertility studies with bortezomib were not performed but evaluation of reproductive tissues has been performed in the general toxicity studies. In the six-month rat toxicity study, degenerative effects in the ovary were observed at doses  $\geq 0.3$  mg/m<sup>2</sup> (one-fourth of the recommended clinical dose), and degenerative changes in the testes occurred at 1.2 mg/m<sup>2</sup>.

### **14.2 Animal Toxicology and/or Pharmacology**

**Cardiovascular Toxicity:** Studies in monkeys showed that administration of dosages approximately twice the recommended clinical dose resulted in heart rate elevations, followed by profound progressive hypotension, bradycardia, and death 12 to 14 hours post dose. Doses  $\geq 1.2$  mg/m<sup>2</sup> induced dose-proportional changes in cardiac parameters. Bortezomib has been shown to distribute to most tissues in the body, including the myocardium. In a repeated dosing toxicity study in the monkey, myocardial hemorrhage, inflammation, and necrosis were also observed.

**Chronic Administration:** In animal studies at a dose and schedule similar to that recommended for patients (twice weekly dosing for two weeks followed by one week rest), toxicities observed included severe anemia and thrombocytopenia, and gastrointestinal, neurological and lymphoid system toxicities. Neurotoxic effects of bortezomib in animal studies included axonal swelling and degeneration in peripheral nerves, dorsal spinal roots, and tracts of the spinal cord. Additionally, multifocal hemorrhage and necrosis in the brain, eye, and heart were observed.

## **15. CLINICAL STUDIES**

### **15.1 Multiple Myeloma**

#### ***Randomized, Open-Label Clinical Study in Patients with Previously Untreated Multiple Myeloma:***

A prospective, international, randomized (1:1), open-label clinical study of 682 patients was conducted to determine whether Bortezomib Taro administered intravenously (1.3 mg/m<sup>2</sup>) in

combination with melphalan (9 mg/m<sup>2</sup>) and prednisone (60 mg/m<sup>2</sup>) resulted in improvement in time to progression (TTP) when compared to melphalan (9 mg/m<sup>2</sup>) and prednisone (60 mg/m<sup>2</sup>) in patients with previously untreated multiple myeloma. Treatment was administered for a maximum of nine cycles (approximately 54 weeks) and was discontinued early for disease progression or unacceptable toxicity. Antiviral prophylaxis was recommended for patients on the Bortezomib Taro study arm.

The median age of the patients in the study was 71 years (48;91), 50% were male, 88% were Caucasian and the median Karnofsky performance status score for the patients was 80 (60;100). Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105g/L (64;165), and a median platelet count of 221,500/microliter (33,000;587,000).

Efficacy results for the trial are presented in Table 15. At a pre-specified interim analysis (with median follow-up of 16.3 months), the combination of Bortezomib Taro, melphalan and prednisone therapy resulted in significantly superior results for time to progression, progression-free survival, overall survival and response rate. Further enrollment was halted, and patients receiving melphalan and prednisone were offered Bortezomib Taro in addition. A later, pre-specified analysis of overall survival (with median follow-up of 36.7 months with a hazard ratio of 0.65, 95% CI: 0.51, 0.84) resulted in a statistically significant survival benefit for the Bortezomib Taro, melphalan and prednisone treatment arm despite subsequent therapies including Bortezomib Taro based regimens. In an updated analysis of overall survival based on 387 deaths (median follow-up 60.1 months), the median overall survival for the Bortezomib Taro, melphalan and prednisone treatment arm was 56.4 months and for the melphalan and prednisone treatment arm was 43.1 months, with a hazard ratio of 0.695 (95% CI: 0.57, 0.85).

**TABLE 15 - Summary of Efficacy Analyses in the Previously Untreated Multiple Myeloma Study**

<b>Efficacy endpoint</b>	<b>Bortezomib Taro, Melphalan and Prednisone (n=344)</b>	<b>Melphalan and Prednisone (n=338)</b>
<b>Time to progression</b>		
Events n (%)	101 (29)	152 (45)
Median* (months) (95% CI)	20.7 (17.6, 24.7)	15.0 (14.1, 17.9)
Hazard ratio† (95% CI)	0.54 (0.42, 0.70)	
p-value‡	0.000002	
<b>Progression-Free survival</b>		
Events n (%)	135 (39)	190 (56)
Median* (months) (95% CI)	18.3 (16.6, 21.7)	14.0 (11.1, 15.0)
Hazard ratio† (95% CI)	0.61 (0.49, 0.76)	
p-value‡	0.00001	
<b>Response rate</b>		
CR§ n (%)	102 (30)	12 (4)
PR§ n (%)	136 (40)	103 (30)
nCR n (%)	5 (1)	0
CR+PR§ n (%)	238 (69)	115 (34)
p-value¶	< 10 <sup>-10</sup>	

Efficacy endpoint	Bortezomib Taro, Melphalan and Prednisone (n=344)	Melphalan and Prednisone (n=338)
<b>Overall Survival at Median Follow Up of 36.7 Months</b>		
Events (deaths) n (%)	109 (32)	148 (44)
Median* (months) (95% CI)	Not reached (46.2, NR)	43.1 (34.8, NR)
Hazard ratio† (95% CI)	0.65 (0.51, 0.84)	
p-value‡	0.00084	

Note: All results are based on the analysis performed at a median follow-up duration of 16.3 months except for the overall survival analysis.

\* Kaplan-Meier estimate.

† Hazard ratio estimate is based on a Cox proportional-hazard model adjusted for stratification factors: beta<sub>2</sub>-microglobulin, albumin, and region. A hazard ratio less than one indicates an advantage for Bortezomib Taro, melphalan and prednisone


‡ p-value based on the stratified log-rank test adjusted for stratification factors: beta<sub>2</sub>-microglobulin, albumin, and region

§ EBMT criteria

¶ p-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors


TTP was statistically significantly longer on the Bortezomib Taro, melphalan and prednisone arm (see Figure 1). (median follow up 16.3 months)

**FIGURE 1: Time to Progression Bortezomib Taro, Melphalan and Prednisone vs Melphalan and Prednisone**



Overall survival was statistically significantly longer on the Bortezomib Taro, Melphalan and Prednisone arm (see Figure 2). (median follow up 60.1 months)

**FIGURE 2: Overall Survival Bortezomib Taro, Melphalan and Prednisone vs Melphalan and Prednisone**



**Randomized, Clinical Study in Relapsed Multiple Myeloma of Bortezomib Taro vs Dexamethasone**

A prospective Phase 3, international, randomized (1:1), stratified, open-label clinical study (NTC00048230) enrolling 669 patients was designed to determine whether Bortezomib Taro resulted in improvement in time to progression (TTP) compared to high-dose dexamethasone in patients with progressive multiple myeloma following 1 to 3 prior therapies. Patients considered to be refractory to prior high-dose dexamethasone were excluded as were those with baseline grade  $\geq 2$  peripheral neuropathy or platelet counts  $< 50,000/\mu\text{L}$ . A total of 627 patients were evaluable for response.

Stratification factors were based on the number of lines of prior therapy the patient had previously received (1 previous line vs more than 1 line of therapy), time of progression relative to prior treatment (progression during or within 6 months of stopping their most recent therapy vs relapse  $> 6$  months after receiving their most recent therapy), and screening beta<sub>2</sub>-microglobulin levels ( $\leq 2.5$  mg/L vs  $> 2.5$  mg/L).

Baseline patient and disease characteristics are summarized in Table 16.

**TABLE 16 - Summary of Baseline Patient and Disease Characteristics in the Relapsed Multiple Myeloma Study**

	<b>Bortezomib Taro (n=333)</b>	<b>Dexamethasone (n=336)</b>
<b>Patient Characteristics</b>		
Median age in years (range)	62.0 (33, 84)	61.0 (27, 86)
Gender: male/female	56% / 44%	60% / 40%
Race: Caucasian/black/other	90% / 6% / 4%	88% / 7% / 5%
Karnofsky performance status score $\leq 70$	13%	17%
Hemoglobin $< 100$ g/L	32%	28%
Platelet count $< 75 \times 10^9/\text{L}$	6%	4%
<b>Disease Characteristics</b>		
Type of myeloma (%): IgG/IgA/Light chain	60% / 23% / 12%	59% / 24% / 13%
Median beta <sub>2</sub> -microglobulin (mg/L)	3.7	3.6
Median albumin (g/L)	39.0	39.0
Creatinine clearance $\leq 30$ mL/min [n (%)]	17 (5%)	11 (3%)

<b>Median Duration of Multiple Myeloma Since Diagnosis (Years)</b>	3.5	3.1
<b>Number of Prior Therapeutic Lines of Treatment</b>		
Median	2	2
1 prior line	40%	35%
> 1 prior line	60%	65%
<b>Previous Therapy</b>		
Any prior steroids, e.g., dexamethasone, VAD	98%	99%
Any prior anthracyclines, e.g., VAD, mitoxantrone	77%	76%
Any prior alkylating agents, e.g., MP, VBMCP	91%	92%
Any prior thalidomide therapy	48%	50%
Vinca alkaloids	74%	72%
Prior stem cell transplant/other high-dose therapy	67%	68%
Prior experimental or other types of therapy	3%	2%

Patients in the Bortezomib Taro treatment group were to receive 8 three-week treatment cycles followed by 3 five-week treatment cycles of Bortezomib Taro. Patients achieving a CR were treated for four cycles beyond first evidence of CR. Within each three-week treatment cycle, Bortezomib Taro 1.3 mg/m<sup>2</sup>/dose alone was administered by intravenous bolus twice weekly for two weeks on Days 1, 4, 8, and 11 followed by a ten-day rest period (Days 12 to 21). Within each five-week treatment cycle, Bortezomib Taro 1.3 mg/m<sup>2</sup>/dose alone was administered by intravenous bolus once weekly for four weeks on Days 1, 8, 15, and 22 followed by a 13-day rest period (Days 23 to 35) [see *Dosage and Administration (4.4)*].

Patients in the dexamethasone treatment group were to receive 4, five-week treatment cycles followed by 5 four-week treatment cycles. Within each five-week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4, 9 to 12, and 17 to 20 followed by a 15-day rest period (Days 21-35). Within each 4-week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4 followed by a 24-day rest period (Days 5 to 28). Patients with documented progressive disease on dexamethasone were offered Bortezomib Taro at a standard dose and schedule on a companion study. Following a preplanned interim analysis of time to progression, the dexamethasone arm was halted and all patients randomized to dexamethasone were offered Bortezomib Taro, regardless of disease status.

In the Bortezomib Taro arm, 34% of patients received at least one Bortezomib Taro dose in all 8 of the three-week cycles of therapy, and 13% received at least one dose in all 11 cycles. The average number of Bortezomib Taro doses during the study was 22, with a range of 1 to 44. In the dexamethasone arm, 40% of patients received at least one dose in all 4 of the five-week treatment cycles of therapy, and 6% received at least one dose in all nine cycles.

The time to event analyses and response rates from the relapsed multiple myeloma study are presented in Table 17. Response and progression were assessed using the European Group for Blood and Marrow Transplantation (EBMT) criteria. Complete response (CR) required < 5% plasma cells in the marrow, 100% reduction in M-protein, and a negative immunofixation test (IF-). Partial Response (PR) requires ≥50% reduction in serum myeloma protein and ≥90% reduction of urine myeloma protein on at least two occasions for a minimum of at least six weeks along with stable bone disease and normal calcium. Near complete response (nCR) was defined as meeting all the criteria for complete response including 100% reduction in M-protein by protein electrophoresis, however M-protein was still detectable by immunofixation (IF+).

**TABLE 17 - Summary of Efficacy Analyses in the Relapsed Multiple Myeloma Study**

Efficacy Endpoint	All Patients		1 Prior Line of Therapy		> 1 Prior Line of Therapy	
	Bortezomib Taro	Dex	Bortezomib Taro	Dex	Bortezomib Taro	Dex
	(n=333)	(n=336)	(n=132)	(n=119)	(n=200)	(n=217)
<b>Time to Progression</b>						
Events n (%)	147 (44)	196 (58)	55 (42)	64 (54)	92 (46)	132 (61)
Median <sup>a</sup> (95% CI)	6.2 mo (4.9, 6.9)	3.5 mo (2.9, 4.2)	7.0 mo (6.2, 8.8)	5.6 mo (3.4, 6.3)	4.9 mo (4.2, 6.3)	2.9 mo (2.8, 3.5)
Hazard ratio <sup>b</sup> (95% CI)	0.55 (0.44, 0.69)		0.55 (0.38, 0.81)		0.54 (0.41, 0.72)	
p-value <sup>c</sup>	< 0.0001		0.0019		< 0.0001	
<b>Overall Survival</b>						
Events (deaths) n (%)	51 (15)	84 (25)	12 (9)	24 (20)	39 (20)	60 (28)
Hazard ratio <sup>b</sup> (95% CI)	0.57 (0.40, 0.81)		0.39 (0.19, 0.81)		0.65 (0.43, 0.97)	
p-value <sup>c,d</sup>	< 0.05		< 0.05		< 0.05	
<b>Response Rate</b>						
Population <sup>e</sup> n = 627	n=315	n=312	n=128	n=110	n=187	n=202
CR <sup>f</sup> n (%)	20 (6)	2 (<1)	8 (6)	2 (2)	12 (6)	0 (0)
PR <sup>f</sup> n (%)	101 (32)	54 (17)	49 (38)	27 (25)	52 (28)	27 (13)
nCR <sup>f,g</sup> n (%)	21 (7)	3 (<1)	8 (6)	2 (2)	13 (7)	1 (<1)
CR + PR <sup>f</sup> n (%)	121 (38)	56 (18)	57 (45)	29 (26)	64 (34)	27 (13)
p-value <sup>h</sup>	< 0.0001		0.0035		< 0.0001	

<sup>a</sup> Kaplan-Meier estimate

<sup>b</sup> Hazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than one indicates an advantage for Bortezomib Taro.

<sup>c</sup> p-value based on the stratified log-rank test including randomization stratification factors.

<sup>d</sup> Precise p-value cannot be rendered.

<sup>e</sup> Response population includes patients who had measurable disease at baseline and received at least one dose of study drug.


<sup>f</sup> EBMT criteria; nCR meets all EBMT criteria for CR but has positive IF. Under EBMT criteria nCR is in the PR category.

<sup>g</sup> In two patients, the IF was unknown.

<sup>h</sup> p-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors.


TTP was statistically significantly longer on the bortezomib arm (*see Fig. 3*).

**FIGURE 3: Time to Progression Bortezomib Taro vs Dexamethasone (Relapsed Multiple Myeloma Study)**



As shown in Figure 4, Bortezomib Taro had a significant survival advantage relative to dexamethasone ( $p < 0.05$ ). The median follow-up was 8.3 months.

**FIGURE 4: Overall Survival Bortezomib Taro vs Dexamethasone (Relapsed Multiple Myeloma Study)**



For the 121 patients achieving a response (CR or PR) on the Bortezomib Taro arm, the median duration was 8.0 months (95% CI: 6.9, 11.5 months) compared to 5.6 months (95% CI: 4.8, 9.2 months) for the 56 responders on the dexamethasone arm. The response rate was significantly higher on the Bortezomib Taro arm regardless of beta<sub>2</sub>-microglobulin levels at baseline.



**Randomized, Open-Label Clinical Study of Bortezomib Taro Subcutaneous vs Intravenous in Relapsed Multiple Myeloma**

An open-label, randomized, Phase 3 non-inferiority study (NCT00722566) compared the efficacy and safety of the subcutaneous administration of Bortezomib Taro vs the intravenous administration. This study included 222 bortezomib naïve patients with relapsed multiple myeloma, who were randomized in a 2:1 ratio to receive 1.3 mg/m<sup>2</sup> of Bortezomib Taro by either the subcutaneous (n=148) or intravenous (n=74) route for eight cycles. Patients who did not obtain an optimal response (less than Complete Response (CR)) to therapy with Bortezomib Taro alone after four cycles were allowed to receive oral dexamethasone 20 mg daily on the day of and after Bortezomib Taro administration (82 patients in subcutaneous treatment group and 39 patients in the intravenous treatment group). Patients with baseline Grade ≥ 2 peripheral neuropathy or neuropathic pain, or platelet counts < 50,000/μL were excluded. A total of 218 patients were evaluable for response.

Stratification factors were based on the number of lines of prior therapy the patient had received (one previous line vs more than one line of therapy), and international staging system (ISS) stage (incorporating beta<sub>2</sub>-microglobulin and albumin levels; Stages I, II, or III).

The baseline demographic and other characteristics of the two treatment groups are summarized as follows: the median age of the patient population was approximately 64 years of age (range: 38-88 years), primarily male (subcutaneous: 50%, intravenous: 64%); the primary type of myeloma is IgG (subcutaneous: 65% IgG, 26% IgA, 8% light chain; intravenous: 72% IgG, 19% IgA, 8% light chain), ISS staging I/II/III (%) was 27, 41, 32 for both subcutaneous and intravenous, Karnofsky performance status score was ≤ 70% in 22% of subcutaneous and 16% of intravenous, creatinine clearance was 67.5 mL/min in subcutaneous and 73 mL/min in intravenous, the median years from diagnosis was 2.68 and 2.93 in subcutaneous and intravenous respectively and the proportion of patients with more than one prior line of therapy was 38% in subcutaneous and 35% in intravenous.

This study met its primary (non-inferiority) objective that single agent subcutaneous Bortezomib Taro retains at least 60% of the overall response rate after four cycles relative to single agent intravenous Bortezomib Taro. The results are provided in Table 18.

**TABLE 18 - Summary of Efficacy Analyses in the Relapsed Multiple Myeloma Study of Bortezomib Taro Subcutaneous vs Intravenous**

	<b>Subcutaneous Bortezomib Taro</b>	<b>Intravenous Bortezomib Taro</b>
<b>Intent to Treat Population</b>	<b>(n=148)</b>	<b>(n=74)</b>
<b>Primary Endpoint</b>		
<b>Response Rate at 4 Cycles</b>		
ORR (CR + PR) n (%)	63 (43)	31 (42)
Ratio of Response Rates (95% CI)	1.01 (0.73, 1.40)	
CR n (%)	11 (7)	6 (8)
PR n (%)	52 (35)	25 (34)
nCR n (%)	9 (6)	4 (5)
<b>Secondary Endpoints</b>		
<b>Response Rate at 8 Cycles</b>		
ORR (CR + PR)	78 (53)	38 (51)
CR n (%)	17 (11)	9 (12)
PR n (%)	61 (41)	29 (39)
nCR n (%)	14 (9)	7 (9)
<b>Median Time to Progression, months</b>	10.4	9.4
<b>Median Progression-Free Survival, months</b>	10.2	8.0
<b>1-Year Overall Survival (%)<sup>a</sup></b>	72.6	76.7

<sup>a</sup> Median duration of follow-up is 11.8 months

### ***A Randomized, Phase 2 Dose-Response Study in Relapsed Multiple Myeloma***

An open-label, multicenter study randomized 54 patients with multiple myeloma who had progressed or relapsed on or after front-line therapy to receive Bortezomib Taro 1 mg/m<sup>2</sup> or 1.3 mg/m<sup>2</sup> intravenous bolus twice weekly for two weeks on Days 1, 4, 8, and 11 followed by a ten-day rest period (Days 12 to 21). The median duration of time between diagnosis of multiple myeloma and first dose of Bortezomib Taro on this trial was two years, and patients had received a median of one prior line of treatment (median of three prior therapies). A single complete response was seen at each dose. The overall response rates (CR + PR) were 30% (8/27) at 1 mg/m<sup>2</sup> and 38% (10/26) at 1.3 mg/m<sup>2</sup>.

### ***A Phase 2 Open-Label Extension Study in Relapsed Multiple Myeloma***

Patients from the two Phase 2 studies, who in the investigators' opinion would experience additional clinical benefit, continued to receive Bortezomib Taro beyond 8 cycles on an extension study. Sixty-three (63) patients from the Phase 2 multiple myeloma studies were enrolled and received a median of seven additional cycles of Bortezomib Taro therapy for a total median of 14 cycles (range: 7 to 32). The overall median dosing intensity was the same in both the parent protocol and extension study. Sixty-seven percent (67%) of patients initiated the extension study at the same or higher dose intensity at which they completed the parent protocol, and 89% of patients maintained the standard three-week dosing schedule during the extension study. No new cumulative or new long-term toxicities were observed with prolonged Bortezomib Taro treatment [see *Adverse Reactions (8.1)*].

### ***A Single-Arm Trial of Retreatment in Relapsed Multiple Myeloma***

A single-arm, open-label trial (NCT00431769) was conducted to determine the efficacy and safety of retreatment with Bortezomib Taro. One hundred and thirty patients (≥18 years of age) with multiple myeloma who previously had at least partial response on a Bortezomib Taro -containing regimen (median of two prior lines of therapy [range: 1 to 7]) were retreated upon progression with Bortezomib Taro administered intravenously. Patients were excluded from trial participation if they had peripheral neuropathy or neuropathic pain of Grade ≥ 2. At least six months after prior Bortezomib Taro therapy, Bortezomib Taro was restarted at the last tolerated dose of 1.3 mg/m<sup>2</sup> (n=93) or ≤1 mg/m<sup>2</sup> (n=37) and given on Days 1, 4, 8 and 11 every three weeks for maximum of eight cycles either as single agent or in combination with dexamethasone in accordance with the standard of care. Dexamethasone was administered in combination with Bortezomib Taro to 83 patients in Cycle 1 with an additional 11 patients receiving dexamethasone during the course of Bortezomib Taro retreatment cycles.

The primary endpoint was best confirmed response to retreatment as assessed by European Group for Blood and Marrow Transplantation (EBMT) criteria. Fifty of the 130 patients achieved a best confirmed response of Partial Response or better for an overall response rate of 38.5% (95% CI: 30.1, 47.4). One patient achieved a Complete Response and 49 achieved Partial Response. In the 50 responding patients, the median duration of response was 6.5 months and the range was 0.6 to 19.3 months.

## 15.2 Mantle Cell Lymphoma

### *A Randomized, Open-Label Clinical Study in Patients with Previously Untreated Mantle Cell Lymphoma*

A randomized, open-label, Phase 3 study (NCT00722137) was conducted in 487 adult patients with previously untreated mantle cell lymphoma (Stage II, III or IV) who were ineligible or not considered for bone marrow transplantation to determine whether Bortezomib Taro administered in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) resulted in improvement in progression-free survival (PFS) when compared to the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This clinical study utilized independent pathology confirmation and independent radiologic response assessment.

Patients in the VcR-CAP treatment arm received Bortezomib Taro (1.3 mg/m<sup>2</sup>) administered intravenously on days 1, 4, 8, and 11 (rest period Days 12-21); rituximab (375 mg/m<sup>2</sup>) on Day 1; cyclophosphamide (750 mg/m<sup>2</sup>) on Day 1; doxorubicin (50 mg/m<sup>2</sup>) on Day 1; and prednisone (100 mg/m<sup>2</sup>) on Day 1 through Day 5 of the 21-day treatment cycle. For patients with a response first documented at Cycle 6, two additional treatment cycles were allowed.

Median patient age was 66 years, 74% were male, 66% were Caucasian and 32% were Asian. 69% of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for MCL, 54% of patients had an International Prognostic Index (IPI) score of three (high-intermediate) or higher and 76% had Stage IV disease.

The majority of the patients in both groups received six or more cycles of treatment, 84% in the VcR-CAP group and 83% in the R-CHOP group. Median number of cycles received by patients in both treatment arms was six with 17% of patients in the R-CHOP group and 14% of subjects in the VcR-CAP group receiving up to two additional cycles.

The efficacy results for PFS, CR, ORR with a median follow-up of 40 months are presented in Table 19. The response criteria used to assess efficacy were based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (IWRC). Final overall survival results at a median follow-up of 78.5 months are also presented in Table 19 and Figure 6. The combination of VcR-CAP resulted in statistically significant prolongation of PFS compared with R-CHOP (*see Table 18 and Figure 5*).

**TABLE 19 - Summary of Efficacy Analyses in the Previously Untreated Mantle Cell Lymphoma Study**

<b>Efficacy Endpoint n: Intent to Treat patients</b>	<b>VcR-CAP (n=243)</b>	<b>R-CHOP (n=244)</b>
<b>Progression-Free Survival (by independent radiographic assessment)</b>		
Events n (%)	133 (55)	165 (68)
Median <sup>a</sup> (months) (95% CI)	25 (20, 32)	14 (12, 17)
Hazard ratio <sup>b</sup> (95% CI)	0.63 (0.50, 0.79)	
p-value <sup>c</sup>	<0.001	
<b>Complete Response Rate (CR)<sup>d</sup></b>		
n (%) (95% CI)	108 (44) (38, 51)	82 (34) (28, 40)
n (%) (95% CI)	214 (88) (83, 92)	208 (85) (80, 89)
<b>Overall Response Rate (CR+CRu+PR)<sup>e</sup></b>		
n (%) (95% CI)	214 (88) (83, 92)	208 (85) (80, 89)

<b>Overall Survival</b>		
Events n (%)	103 (42)	138 (57)
Median <sup>a</sup> (months) (95% CI)	91 (71, NE)	56 (47, 69)
Hazard Ratio <sup>b</sup> (95% CI)	0.66 (0.51, 0.85)	

Note: All results are based on the analysis performed at a median follow-up duration of 40 months except for the overall survival analysis, which was performed at a median follow-up of 78.5 months.

<sup>a</sup> Based on Kaplan-Meier product limit estimates.

<sup>b</sup> Hazard ratio estimate is based on a Cox's model stratified by IPI risk and stage of disease. A hazard ratio < 1 indicates an advantage for VcR-CAP.


<sup>c</sup> Based on Log rank test stratified with IPI risk and stage of disease.

<sup>d</sup> Includes CR by independent radiographic assessment, bone marrow, and LDH using ITT population.

<sup>e</sup> Includes CR+CRu+PR by independent radiographic assessment, regardless of the verification by bone marrow and LDH, using ITT population.


CI=Confidence Interval; IPI= International Prognostic Index; LDH=Lactate dehydrogenase

**FIGURE 5: Progression-Free Survival VcR-CAP vs R-CHOP (Previously Untreated Mantle Cell Lymphoma Study)**



Key: R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone;  
VcR-CAP=Bortezomib Taro, rituximab, cyclophosphamide, doxorubicin, and prednisone.

**FIGURE 6: Overall Survival VcR-CAP vs R-CHOP (Previously Untreated Mantle Cell Lymphoma Study)**



Key: R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP= Bortezomib Taro, rituximab, cyclophosphamide, doxorubicin, and prednisone.

***A Phase 2 Single-Arm Clinical Study in Relapsed Mantle Cell Lymphoma After Prior Therapy***

The safety and efficacy of Bortezomib Taro in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study (NCT00063713) of 155 patients with progressive disease who had received at least one prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, and 92% were Caucasian. Of the total, 75% had one or more extra-nodal sites of disease, and 77% were stage 4. In 91% of the patients, prior therapy included all of the following: an anthracycline or mitoxantrone, cyclophosphamide, and rituximab. A total of thirty seven percent (37%) of patients were refractory to their last prior therapy. An intravenous bolus injection of Bortezomib Taro 1.3 mg/m<sup>2</sup>/dose was administered twice weekly for two weeks on Days 1, 4, 8, and 11 followed by a ten-day rest period (Days 12 to 21) for a maximum of 17 treatment cycles. Patients achieving a CR or CRu were treated for four cycles beyond first evidence of CR or CRu. The study employed dose modifications for toxicity [see *Dosage and Administration (4.3, 4.4)*].

Responses to Bortezomib Taro are shown in Table 20. Response rates to Bortezomib Taro were determined according to the International Workshop Response Criteria (IWRC) based on independent radiologic review of CT scans. The median number of cycles administered across all patients was four; in responding patients the median number of cycles was eight. The median time to response was 40 days (range: 31 to 204 days). The median duration of follow-up was more than 13 months.

**TABLE 20 - Response Outcomes in a Phase 2 Relapsed Mantle Cell Lymphoma Study**

Response Analyses (N = 155)	N (%)	95% CI
Overall Response Rate (IWRC) (CR + CRu + PR)	48 (31)	(24, 39)
Complete Response (CR + CRu)	12 (8)	(4, 13)
CR	10 (6)	(3, 12)
CRu	2 (1)	(0, 5)
Partial Response (PR)	36 (23)	(17, 31)
<b>Duration of Response</b>	<b>Median</b>	<b>95% CI</b>
CR + CRu + PR (n=48)	9.3 months	(5.4, 13.8)
CR + CRu (n=12)	15.4 months	(13.4, 15.4)
PR (n=36)	6.1 months	(4.2, 9.3)

### ***Clinical Efficacy in Previously Untreated Mantle Cell Lymphoma (MCL)***

Study LYM-3002 was a Phase 3, randomised, open-label study comparing the efficacy and safety of the combination of Bortezomib Taro, rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV). Patients in the VcR-CAP treatment arm received Bortezomib Taro (1.3 mg/m<sup>2</sup>; on days 1, 4, 8, 11, rest period days 12-21), rituximab 375 mg/m<sup>2</sup> intravenous on day 1; cyclophosphamide 750 mg/m<sup>2</sup> intravenous on day 1; doxorubicin 50 mg/m<sup>2</sup> intravenous on day 1; and prednisone 100 mg/m<sup>2</sup> orally on day 1 through day 5 of the 21 day Bortezomib Taro treatment cycle. For patients with a response first documented at cycle 6, two additional treatment cycles were given.

The primary efficacy endpoint was progression-free survival based on Independent Review Committee (IRC) assessment. Secondary endpoints included, time to progression (TTP), time to next anti-lymphoma treatment (TNT), duration of treatment free interval (TFI), overall response rate (ORR) and complete response (CR/CRu) rate, overall survival (OS) and response duration.

The demographic and baseline disease characteristics were generally well balanced between the two treatment arms: median patient age was 66 years, 74% were male, 66% were Caucasian and 32% Asian, 69% of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for MCL, 54% of patients had an International Prognostic Index (IPI) score of  $\geq 3$ , and 76% had Stage IV disease. Treatment duration (median=17 weeks) and duration of follow-up (median=40 months) were comparable in both treatment arms. A median of six cycles was received by patients in both treatment arms with 14% of subjects in the VcR-CAP group and 17% of patients in the R-CHOP group receiving 2 additional cycles. The majority of the patients in both groups completed treatment, 80% in the VcR-CAP group and 82% in the R-CHOP group. Efficacy results are presented in Table 21:

**TABLE 21: Efficacy Results from Study LYM-3002**

<b>Efficacy endpoint</b>	<b>VcR-CAP</b>	<b>R-CHOP</b>	
n: ITT patients	243	244	
<b>Progression free survival (IRC)<sup>a</sup></b>			
Events n (%)	133 (54.7%)	165 (67.6%)	HR <sup>b</sup> (95% CI)=0.63 (0.50; 0.79)
Median <sup>c</sup> (95% CI) (months)	24.7 (19.8; 31.8)	14.4 (12; 16.9)	p-value <sup>d</sup> < 0.001
<b>Response rate</b>			
n: response-evaluable patients	229	228	
Overall complete response (CR+CRu) <sup>f</sup> n (%)	122 (53.3%)	95 (41.7%)	OR <sup>e</sup> (95% CI) = 1.688 (1.148; 2.481) p-value <sup>g</sup> =0.007
Overall response (CR+CRu+PR) <sup>h</sup> n (%)	211 (92.1%)	204 (89.5%)	OR <sup>e</sup> (95% CI) = 1.428 (0.749; 2.722) p-value <sup>g</sup> = 0.275

- <sup>a</sup> Based on Independent Review Committee (IRC) assessment (radiological data only).
- <sup>b</sup> Hazard ratio estimate is based on a Cox's model stratified by IPI risk and stage of disease. A hazard ratio < 1 indicates an advantage for VcR-CAP.
- <sup>c</sup> Based on Kaplan-Meier product limit estimates.
- <sup>d</sup> Based on Log rank test stratified with IPI risk and stage of disease.
- <sup>e</sup> Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors. An odds ratio (OR) > 1 indicates an advantage for VcR-CAP.
- <sup>f</sup> Include all CR+CRu, by IRC, bone marrow and LDH.
- <sup>g</sup> P-value from the Cochran Mantel-Haenszel chi-square test, with IPI and stage of disease as stratification factors.
- <sup>h</sup> Include all radiological CR+CRu+PR by IRC regardless the verification by bone marrow and LDH.
- CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response;  
CI=Confidence Interval, HR=Hazard Ratio; OR=Odds Ratio; ITT=Intent to Treat

Median PFS by investigator assessment was 30.7 months in the VcR-CAP group and 16.1 months in the R-CHOP group (Hazard Ratio [HR]=0.51;  $p < 0.001$ ). A statistically significant benefit ( $p < 0.001$ ) in favour of the VcR-CAP treatment group over the R-CHOP group was observed for TTP (median 30.5 vs 16.1 months), TNT (median 44.5 vs 24.8 months) and TFI (median 40.6 vs 20.5 months). The median duration of complete response was 42.1 months in the VcR-CAP group compared with 18 months in the R-CHOP group. The duration of overall response was 21.4 months longer in the VcR-CAP group (median 36.5 months vs 15.1 months in the R-CHOP group). The final analysis for OS was performed after a median follow-up of 82 months. Median OS was 90.7 months for the VcR-CAP group compared with 55.7 months for the R-CHOP group (HR=0.66;  $p=0.001$ ). The observed final median difference in the OS between the two treatment groups was 35 months.

## **16. HOW SUPPLIED/STORAGE AND HANDLING**

Bortezomib Taro 3.5 mg is supplied as individually cartoned 10 mL vials containing 3.5 mg of bortezomib as a white to off-white lyophilized powder or cake.

Bortezomib Taro 3.5 mg is available in cartons containing one single-use vial.

There have been fatal cases of inadvertent intrathecal administration of Bortezomib Taro. Bortezomib Taro is authorized for intravenous or subcutaneous use only.

### ***Stability:***

Unopened vials of Bortezomib Taro 3.5 mg are stable until the date indicated on the package when stored in the original package protected from light.

Keep the vial in the outer carton in order to protect from light. Do not store above 25°C.

### **DO NOT ADMINISTER BORTEZOMIB TARO INTRATHECALLY.**

Consider handling and disposal of Bortezomib Taro 3.5 mg according to guidelines issued for cytotoxic drugs, including the use of gloves and other protective clothing to prevent skin contact.

Reconstituted solution:

From a microbiological point of view, the reconstituted solution should be used immediately after preparation. If the reconstituted solution is not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. However, the chemical and physical in-use stability of the reconstituted solution has been demonstrated for 8 hours at 25 °C stored in the original vial and/or a syringe. The total storage time for the reconstituted medicinal product should not exceed 8 hours prior to administration.

**LICENSE HOLDER AND MANUFACTURER**

**Name and address of the manufacturer and the license holder**

Taro International Ltd., 14 Hakitor St., Haifa Bay 2624761, Israel

**MARKETING REGISTRATION NUMBER**

162-44-35830-00

Revised in December 2022 according to MoH guidelines.